|
 |
|
POSTER PRESENTATIONS
SESSION II |
METHODS & CONCEPTS |
|
PMC1
|
SIMULATION
MODELING
OF
CARDIOVASCULAR
DISEASE:
IS
APPLYING
AVERAGE
LIFE
EXPECTANCY
TO ALL
SURVIVORS
DETAILED
ENOUGH?
|
|
|
Proskorovsky
I1,
Ishak KJ1,
Migliaccio-Walle
K2,
Caro JJ2 |
|
|
1Caro
Research
Institute,
Dorval,
QC,
Canada,
2Caro
Research
Institute,
Concord,
MA, USA
|
|
PMC2
|
EFFICIENT
DATA
MINING
AND
PROBABILISTIC
INFERENCE
WITH
P-COURSE:
A
BAYESIAN
METHOD
WITH
MULTILEVEL
PRIORS
FOR
MEDICAL
APPLICATIONS
|
|
|
Soini EJ1, Martikainen JA2, Lahtinen J3,
Myllymäki
P3,
Kontkanen
P3,
Valtonen
H4,
Ryynänen
OP5 |
|
|
1Department
of
Health
Policy
and
Management,
Department
of
Social
Pharmacy,
University
of
Kuopio,
Kuopio,
Finland,
2Centre
for
Pharmaceutical
Policy
and
Economics
(CEPPE),
Department
of
Social
Pharmacy,
University
of
Kuopio,
Kuopio,
Finland,
3Complex
Systems
Computation
Research
Group (CoSCo),
Helsinki
Institute
for
Information
Technology
(HIIT),
University
of
Helsinki,
Helsinki,
Finland,
4Department
of
Health
Policy
and
Management,
University
of
Kuopio,
Kuopio,
Finland,
5General
Practice,
Department
of
Public
Health
and
Clinical
Nutrition,
University
of
Kuopio,
Kuopio,
Finland
|
|
PMC3
|
WITHDRAWN |
|
|
|
|
PMC4
|
PRESENTING
IGNORANCE:
A
POSSIBILITY
INTERVAL
APPROACH
TO
DEPICT
HIGH-LEVEL
UNCERTAINTY
DUE TO
CENSORING
OR
NON-RESPONDENTS
|
|
|
Turunen
JH1,
Soini EJ2 |
|
|
1Equal
contribution
of both
authors.
Department
of
Social
Pharmacy,
University
of
Kuopio,
Kuopio,
Finland,
2Department
of
Social
Pharmacy,
Department
of
Health
Policy
and
Management,
University
of
Kuopio,
Kuopio,
Finland
|
|
 |
|
PMC5
|
INDIRECT
COSTS OF
COMMON
COLD IN
GERMANY
|
|
|
Hessel
FP,
Wasem J |
|
|
University
of
Duisburg-Essen,
Essen,
Germany
|
|
PMC6
|
IMPLEMENTING
NATURAL
HISTORY
STUDIES
IN
EURASIA:
THE
NIEMANN-PICK
EXPERIENCE
WITH
RAPIDLY
CHANGING
NATIONAL
REGULATIONS
|
|
|
Madison
M1, Finegan Y1, Sawyer R2, Koval S2,
Cox G2 |
|
|
1Abt
Associates
Inc,
Lexington,
MA, USA,
2Genzyme
Corporation,
Cambridge,
MA, USA
|
|
PMC7
|
Withdrawn |
|
PMC8
|
ECONOMIC
DECISION
MODELLING:
CALCULATION
OF TOTAL
NET
MONETARY
BENEFITS
OF
GUIDELINE
IMPLEMENTATION
INTO
CLINICAL
PRACTICE
|
|
|
Hoomans
T1, Ament A1, Evers S2, Severens JL3 |
|
|
1Maastricht
University,
Maastricht,
The
Netherlands,
2Maastricht
University,
Maastricht,
Nepal,
3Academic
Hospital
Maastricht,
Maastricht,
The
Netherlands
|
|
PMC9
|
A REVIEW
OF
FACTORS
AFFECTING
THERAPEUTIC
COMPLIANCE
|
|
|
Jin J,
Li SC |
|
|
National
University
of
Singapore,
Singapore,
Singapore
|
|
PMC10
|
ESTIMATING
UTILITY
VALUES
FOR
HEALTH
STATUS
USING
THE
SPANISH
VERSION
OF THE
SF-36.
IS IT
WORTHY
TO
CALCULATE
WEIGHT
VALUES
FOR
UTILITY
MEASURES?
|
|
|
Rebollo
P1, Morís J1, Prieto L2, Ortega F3,
Ortega T3 |
|
|
1BAP
Health
Outcomes,
Oviedo,
Spain,
2Madrid,
San
Agustín
de
Guadalíx,
Madrid,
Spain,
3Hospital
Universitario
Central
de
Asturias,
Oviedo,
Spain
|
|
PMC11
|
EFFECTIVE
USE OF
ELECTRONIC
DATA
CAPTURE
(EDC) TO
IMPROVE
THE
QUALITY
AND
EFFICIENCY
OF THE
ANALYSIS
OF
PATIENT
REPORTED
OUTCOMES
|
|
|
Ooms KL |
|
|
Statwood,
HITCHIN,
Hertfordshire,
UK
|
|
PMC12
|
REVIEW
ON THE
IMPACT
OF DOSE
FREQUENCY
ON
COMPLIANCE
AND
HEALTH
OUTCOMES
|
|
|
Shi L1,
Hodges M1,
Yurgin
NR2,
Secnik K2 |
|
|
1Tulane
University,
New
Orleans,
LA, USA,
2Eli
Lilly
and
Company,
Indianapolis,
IN, USA
|
|
PMC13
|
EMPIRICAL
RESEARCH
FOR
WILLINGNESSTO
PAYFOR
ONE QALY
GAIN
|
|
|
Ohkusa Y,
Sugawara
T |
|
|
National
Institute
of
Infectious
Diseases,
Shinjuku,
Tokyo,
Japan
|
|
PMC14
|
MEASURING
PATIENT-REPORTED
SIDE
EFFECTS
OF
DRUGS:
ITS
IMPORTANCE
AND
METHODOLOGICAL
CHALLENGES.
|
|
|
Foster
JM1, Van der Molen T1, Caeser M2,
Hannaford
P3 |
|
|
1University
of
Groningen,
Groningen,
The
Netherlands,
2ALTANA
Pharma
AG,
Konstanz,
Germany,
3University
of
Aberdeen,
Aberdeen,
Scotland,
UK
|
|
PMC15
|
HOSPITAL
PHARMACY
DRUG
DELIVERY
TIME: A
WORK
FLOW
MANAGEMENT
ISSUE
|
|
|
Pierce
CA1, Baker JJ2, McClard C2 |
|
|
1The
Resource
Group,
Richfield,
OH, USA,
2The
Resource
Group,
Pickton,
TX, USA
|
|
PMC16
|
PROPOSED
CHANGES
TO
PHYSICIAN
FEE
SCHEDULE:
2007
PRACTICE
EXPENSE
CONCEPTUAL
METHODOLOGY
|
|
|
Pierce
CA1, Baker JJ2 |
|
|
1The
Resource
Group,
Richfield,
OH, USA,
2The
Resource
Group,
Pickton,
TX, USA
|
|
PMC17
|
MONITORING
OF
PHARMACEUTICAL
COST OF
REIMBURSED
MEDICINES
BY
COMBINING
OFFICIAL
PHARMACY
INVOICE
DATA
WITH
COMMERCIAL
IMS
SALES
DATA.
|
|
|
Van
Wilder P,
Arickx
F, Van
Haeren
E,
Bormans
V |
|
|
RIZIV-INAMI,
Brussels,
Belgium
|
|
PMC18
|
USING
DISTANCE
LEARNING
TO
UNDERSTAND
DISCRETE
EVENT
SIMULATION
|
|
|
Hunting
B,
Moller
J, Caro
JJ |
|
|
Caro
Research
Institute,
Concord,
MA, USA
|
|
|
|
CANCER |
|
Clinical
Outcomes
Studies |
|
PCN1
|
THE
EPIDEMIOLOGIC,
HEALTH-RELATED
QUALITY
OF LIFE,
AND
ECONOMIC
BURDEN
OF
GASTROINTESTINAL
STROMAL
TUMORS
|
|
|
Reddy P1, Boci K2, Charbonneau C3, Pashos CL1 |
|
|
1Abt
Associates
Inc,
Lexington,
MA, USA,
2Abt
Associates
Inc,
Bethesda,
MD, USA,
3Pfizer,
New
York,
NY, USA
|
|
PCN2
|
INCIDENCE
AND
SURVIVAL
STUDY BY
STAGE
AND
ESTIMATED
PREVALENCE
OF RENAL
PARENCHYMA
CANCER
IN
FRANCE
|
|
|
Danzon A1,
Langlois
C1,
Grosclaude
P2,
Colonna
M3,
Delafosse
P3,
Martin E4,
Molinié
F5,
Tretarre
B6,
Velten M7,
Levrat F8 |
|
|
1Registre
des
tumeurs
du
Doubs,
Besançon,
France,
2Tarn
Cancer
registry,
Albi,
France,
3Isere
cancer
registry,
Meylan,
France,
4Somme
cancer
registry,
Amiens,
France,
5Loire
Atlantique
and
Vandée
cancer
redistry,
Nantes,
France,
6Herault
cancer
registry,
Montpelliers,
France,
7Universite
Louis
Pasteur,
strasbourg,
France,
8Pfizer,
Paris,
France
|
|
PCN3
|
EPIDEMIOLOGIC,
HUMANISTIC
AND
ECONOMIC
BURDEN
OF
PATIENTS
WITH
METASTATIC
RENAL
CELL
CARCINOMA
(MRCC)
|
|
|
Banks J1, Gupta K1, Balu S1, Chen E2,
Komatsuzaki
Y2,
Charbonneau
C3,
Pashos
CL1 |
|
|
1Abt
Associates
Inc,
Lexington,
MA, USA,
2Abt
Associates
Inc,
Bethesda,
MD, USA,
3Pfizer,
New
York,
NY, USA
|
|
|
|
Cost
Studies |
|
PCN4
|
A
COMPARATIVE
BUDGET
IMPACT
(BI)
ANALYSIS
OF
ARANESP®
(DARBEPOETIN
ALFA)
500µG
Q3W
VERSUS
OTHER
ERYTHROPOIESIS
STIMULATING
PROTEINS
(ESP) IN
CHEMOTHERAPY-INDUCED
ANEMIA
(CIA) IN
SPAIN
|
|
|
Pérez
Alcántara
F1,
Badia X2,
Arocho R3 |
|
|
1Health
Outcomes
Research,
Barcelona,
Barcelona,
Spain,
2Health
Outcomes
Research
Europe,
Barcelona,
Spain,
3Amgen
SA,
Barcelona,
Barcelona,
Spain
|
|
PCN5
|
HEXVIX
FLUORESCENCE
CYSTOSCOPY
FOR
SUPERFICIAL
BLADDER
CANCER
DIAGNOSIS:
ANALYSIS
OF
BUDGET
IMPACT
ON THE
SWEDISH
HEALTH
SERVICE
|
|
|
Thompson
G1,
Durrant
H2,
Kloster
Y3 |
|
|
1Bridgehead
International
Ltd,
Melton
Mowbray,
Leicestershire,
UK,
2Bridgehead
International
Limited,
Melton
Mowbray,
Leicestershire,
UK,
3Photocure
ASA,
Oslo,
Norway
|
|
PCN6
|
PRIMARY
PROPHYLAXIS
WITH
PEGFILGRASTIM
IS
COST-SAVING
COMPARED
WITH
FILGRASTIM
FOR
BREAST
CANCER
IN SPAIN
|
|
|
Mayordomo
JI1,
Lopez
Pousa A2,
Arocho R3,
Doan QV4,
Dubois R4,
Liu Z4 |
|
|
1Hospital
Clinico
Lozano
Blesa,
Zaragoza,
Spain,
2Hospital
Sant
Pau,
Barcelona,
Spain,
3Amgen
SA,
Barcelona,
Spain,
4Cerner
Health
Insights,
Beverly
Hills,
CA, USA
|
|
PCN7
|
IMPACT
OF
CHANGES
IN THE
FINANCING
OF THE
HEALTH
SERVICES
ON COSTS
STRUCTURE
ON THE
EXAMPLE
OF
CHEMOTHERAPY
OF
ADVANCED
OVARIAN
CANCER
|
|
PCN8
|
RISE OF
HEALTH
RESOURCE
UTILIZATION
AND
COSTS
FOR
SEQUENTIAL
DOCETAXEL
IN
NODE-POSITIVE
PRIMARY
BREAST
CANCER
IN
GERMAN
HOSPITALS
|
|
|
Ihbe-Heffinger
A1,
Wagenpfeil
S1,
Jacobs
VR1,
Gillessen
P1,
Bernard
R1,
Sattler
D2,
Kuhn W3 |
|
|
1Klinikum
rechts
der Isar
der
Technischen
Universität
München,
München,
Germany,
2Städtisches
Krankehaus
München-Harlaching,
München,
Germany,
3Universität
Bonn,
Bonn,
Germany
|
|
PCN9
|
ERLOTINIB
IN
NON-SMALL
CELL
LUNG
CANCER
(NSCLC)
IN
GERMANY
– A
COST-SAVING
SECOND-LINE
TREATMENT
OPTION?
|
|
|
Gabriel
A,
Pirk O,
Kotowa W |
|
|
Fricke &
Pirk
GmbH -
Member
of the
IMS
Health
Group,
Nuremberg,
Germany
|
|
PCN10
|
INCREMENTAL
COST-EFFECTIVENESS
RATIO OF
DARBEPOETIN
ALFA
(ARANESP®)
IN THE
TREATMENT
OF
CHEMOTHERAPY-INDUCED
ANEMIA
IN LUNG
CANCER
PATIENTS
|
|
|
Borget I1, Tilleul P2, Joly AC2, Chouaid C2 |
|
|
1Saint-Antoine
Hospital,
Paris,
France,
France,
2Saint-Antoine
Hospital,
Paris,
France
|
|
PCN11
|
PHARMACOECONOMIC
ANALYSES
OF
ERLOTINIB
COMPARED
WITH
BEST
SUPPORTIVE
CARE
(BSC)
FOR THE
TREATMENT
OF
RELAPSED
NON-SMALL
CELL
LUNG
CANCER
(NSCLC)
FROM THE
CANADIAN
PUBLIC
HEALTHCARE
PERSPECTIVE
|
|
|
Côté I1, Leighl NB2, Gyldmark M3, Maturi B1 |
|
|
1Hoffmann-La
Roche
Limited,
Mississauga,
ON,
Canada,
2Princess
Margaret
Hospital,
Toronto,
ON,
Canada,
3F
Hoffmann
La
Roche,
Basel,
Switzerland
|
|
PCN12
|
COST
EFFECTIVENESS
OF
ERLOTINIB
IN THE
TREATMENT
OF
ADVANCED
NON
SMALL
CELL
LUNG
CANCER
(NSCLC)
IN
POLAND
|
|
|
Orlewska
E1,
Szczesna
A2,
Gyldmark
M3,
Szkultecka-Debek
M4 |
|
|
1Centrum
Farmakoekonomiki,
Warsaw,
Poland,
2Regional
Lung
Diseases
Hospital,
Otwock,
Poland,
3F
Hoffmann
La
Roche,
Basel,
Switzerland,
4Roche
Polska
Sp. z
o.o,
Warsaw,
Poland
|
|
PCN13
|
COST-EFFECTIVENESS
OF
ADJUVANT
CAPECITABINE,
MAYO
CLINIC
AND DE
GRAMONT
REGIMENS
FOR
STAGE
III
COLON
CANCER
IN THE
FRENCH
SETTING
|
|
|
Tilleul
P1, Perrocheau G2, Lafuma A3, Roux E4 |
|
|
1Saint-Antoine
Hospital,
Paris,
France,
2Centre
Renée
Gauducheau,
Saint
Herblain,
France,
3Cemka-Eval,
Bourg-la-Reine,
France,
4Roche,
Neuilly
sur
Seine,
France
|
|
PCN14
|
COST-EFFECTIVENESS
STUDY OF
AN
ASPIRIN
CHEMOPREVENTION
ASSOCIATED
OR NOT
WITH A
COLONOSCOPIC
SURVEILLANCE
IN THE
COLORECTAL
CANCER
|
|
|
Francesconi
C1,
Benamouzig
R2,
Launois
R1 |
|
|
1REES,
Paris,
France,
2Hopital
Avicenne,
Bobigny,
France
|
|
PCN15
|
CAPECITABINE VS. BOLUS 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH DUKES´ C COLON CANCER:
PHARMACOECONOMIC EVALUATION OF X-ACT TRIAL - DATA FROM CZECH PERSPECTIVE
|
|
|
Jiraskova
L1,
Dolezal
T2 |
|
|
1Faculty
of
Pharmacy,
Charles
University,
Hradec
Králové,
Czech
Republic,
2Charles
University,
Prague,
Czech
Republic
|
|
PCN16
|
COST-EFFECTIVENESS
OF
SORAFENIB
VERSUS
BEST
SUPPORTIVE
CARE IN
ADVANCED
RENAL
CELL
CARCINOMA
IN SPAIN
|
|
|
Maroto P1,
Villavicencio
H2,
Piñol C3,
Urruticoechea
L4 |
|
|
1Hospital
de la
Santa
Creu i
Sant
Pau,
Barcelona,
Spain,
2Fundació
Puigvert,
Barcelona,
Spain,
3Q.F.
Bayer,
S.A,
Barcelona,
Spain,
4Q.
F.
Bayer,
S.A,
Barcelona,
Spain
|
|
PCN17
|
COST
EFFECTIVENESS
OF
PRIMARY
PROPHYLAXIS
WITH
PEGFILGRASTIM
OR
FILGRASTIM
IN THE
MEDICAL
TREATMENT
OF
BREAST
CANCER
IN ITALY
|
|
|
Chiroli
S1, Dubois RW2, Doan QV2, Liu Z2,
Heissel
A3,
Palmeri
S4,
Danova M5 |
|
|
1Amgen,
Milan,
Italy,
2Cerner
Health
Insights,
Beverly
Hills,
CA, USA,
3Amgen
Europe,
Zug,
Switzerland,
4Policlinico
Universitario
P.
Giaccone,
Palermo,
Italy,
5Clinica
Medica,
Pavia,
Italy
|
|
PCN18
|
A
SENSITIVITY
ANALYSIS
OF THE
COST PER
QUALITY
ADJUSTED
LIFE
YEAR
(QALY)
OF
TRASTUZUMAB
IN THE
TREATMENT
OF EARLY
BREAST
CANCER
(EBC)
|
|
|
Geary U1, Lewis G2, Erny S3, Gyldmark M4,
Morlotti
L5,
Walzer S6 |
|
|
1Roche
Products
Limited,
Hertfordshire,
UK,
2Roche
Products
Limited,
Welwyn
Garden
City,
Herts,
UK,
3F.
Hoffmann-La
Roche
Pharmaceuticals
AG,
Basel,
Switzerland,
4F.
Hoffmann-La
Roche
Ltd,
Basel,
Switzerland,
5Analytica
Int,
Loerrach,
Germany,
6Analytica
International,
Loerrach,
Germany
|
|
PCN19
|
COST-EFFECTIVENESS
OF
CETUXIMAB
IN
COMBINATION
WITH
RADIOTHERAPY
VERSUS
RADIOTHERAPY
ALONE IN
THE
TREATMENT
OF
LOCALLY
ADVANCED
HEAD AND
NECK
CANCER
IN
SPAIN.
|
|
|
Brosa M1, Robinson P2, Brown B2 |
|
|
1Oblikue
Consulting,
Barcelona,
SC,
Spain,
2IMS
Health,
London,
UK
|
|
PCN20
|
COST-EFFECTIVENESS
ANALYSIS
OF
LETROZOLE
COMPARED
TO
TAMOXIFEN
FOR
TREATMENT
OF EARLY
BREAST
CANCER
IN THE
HUNGARIAN
HEALTH
CARE
SETTING
|
|
|
Kosa J |
|
|
Novartis
Hungary
Ltd,
Budapest,
Pest,
Hungary
|
|
PCN21
|
RETROSPECTIVE
COMPARATIVE
PHARMACOECONOMIC
ANALYSIS
OF
VARIOUS
TREATMENT
SCHEMES
IN
PATIENTS
WITH
ADVANCED
HODGKIN'S
DISEASE
|
|
|
Tolkushin
AG1,
Yagudina
RI1,
Moiseeva
TN2,
Khabriev
RU1 |
|
|
1Moscow
Medical
Academy,
Moscow,
Russia,
2Hematological
Scientific
Center
of the
Russian
Academy
of
Medical
Sciences,
Moscow,
Russia
|
|
PCN22
|
COST-EFFECTIVENESS
(CE) OF
THE
PREVENTION
OF ORAL
MUCOSITIS
(OM)
WITH
KEPIVANCE®
(PALIFERMIN)
IN
PATIENTS
UNDERGOING
MYELOABLATIVE
THERAPY
WITH
AUTOLOGOUS
STEM
CELL
TRANSPLANTATION
(ASCT)
IN
SPAIN.
|
|
|
Brosa M1, Arocho R2 |
|
|
1Oblikue
Consulting,
Barcelona,
SC,
Spain,
2Amgen
SA,
Barcelona,
Spain
|
|
PCN23
|
ADDING
RITUXIMAB
TO
STANDARD
CHEMOTHERAPY
IS COST
NEUTRAL
AND
CLINICALLY
SUPERIOR
IN
ADVANCED
STAGE
NON-HODGKIN'S
LYMPHOMA
(NHL)
|
|
|
Hieke K1, Herold M2 |
|
|
1NEOS
Health,
Binningen,
Switzerland,
2HELIOS
Klinikum
Erfurt,
Erfurt,
Germany
|
|
PCN24
|
PEGFILGRASTIM
PRIMARY
PROPHYLAXIS
IS MORE
COST-EFFECTIVE
THAN
FILGRASTIM
IN WOMEN
WITH
BREAST
CANCER
RECEIVING
CHEMOTHERAPY
IN
FRANCE
|
|
|
Bogillot
O1,
Dubois R2,
Doan QV2,
Liu Z2,
Heissel
A3,
Di Palma
M4 |
|
|
1Amgen
S.A,
Paris,
France,
2Cerner
Health
Insights,
Beverly
Hills,
CA, USA,
3Amgen
Europe,
Zug,
Switzerland,
4Insitut
Gustave
Roussy,
Villejuif
Cedex,
France
|
|
PCN25
|
TREATMENT
OF
ACTINIC
KERATOSIS
(AK) AND
BASAL
CELL
CARCINOMA
(BCC)
WITH
METVIX®
(MAL-PDT)
IN REAL
LIFE
PRACTICE:
A COST
OF
ILLNESS
AND
MODEL
VALIDATION
STUDY
|
|
|
Caekelbergh
K,
Annemans
L |
|
|
IMS
Health
Economics
and
Outcomes
Research
(HEOR),
Brussels,
Belgium
|
|
PCN26
|
PHARMACOECONOMIC
ANALYSIS
IN SPAIN
OF
THERAPY
WITH
ERLOTINIB,
DOCETAXEL,
PEMETREXED
OR BEST
SUPPORTIVE
CARE IN
PATIENTS
WITH
ADVANCED
NON-SMALL
CELL
LUNG
CANCER
WHO HAVE
FAILED
PREVIOUS
CHEMOTHERAPY
REGIMENS
|
|
|
Rubio
Terres C1,
Alvarez
Sanz C2,
Marlene
Gylmark
GM3 |
|
|
1Hero
Consulting,
Madrid,
Spain,
2Roche
Farma,
Madrid,
Spain,
3Hoffman-La
Roche
Inc,
Basel,
Switzerland
|
|
PCN27
|
COST-EFFECTIVENESS
AND
COST-UTILITY
OF
FENTANYL
TTS
(DUROGESIC®
25, 50)
VS.
SR/IR
ORAL
MORPHINES
IN THE
MANAGEMENT
OF
CHRONIC
CANCER
PAIN
|
|
|
Estevez-Carrizo
FE |
|
|
University of Montevideo,
Uruguay,
Montevideo,
Uruguay
|
|
PCN28
|
SHOULD
FOTEMUSTINE
BE USED
AS THE
FIRST
LINE
TREATMENT
|
|
|
Faluta T,
Czech M,
Pachocki
R |
|
|
Servier
Polska,
Warsaw,
Poland
|
|
PCN29
|
ECONOMIC
ADVANTAGES
AND
TIMESAVING
OF USING
OXALIPLATIN
CONCENTRATED
SOLUTION
VERSUS
OXALIPLATIN
LYOPHILISED
POWDER
FOR
INFUSION
|
|
|
Favier B1,
Spath HM2,
Anhoury
P3,
Pacull A3 |
|
|
1Centre
Leon
Berard,
Lyon,
France,
2GRESAC,
Lyon,
France,
3IMS
Health
Consulting
&
Services,
Puteaux,
France
|
|
|
|
PCN30
|
ECONOMIC
EVALUATION
OF
FOLFOX4
VERSUS
FOLFOX7
WITH
OXALIPLATIN
STOP-AND-GO
IN
ADVANCED
COLORECTAL
CANCER
PATIENTS
|
|
|
Tilleul
P1, Jasso Mosqueda G2, Trancart A2,
Joly AC1,
Tournigand
C1,
Maindrault-Goebel
F1,
Le Pen C2,
De
Gramont
A1 |
|
|
1Saint-Antoine
Hospital,
Paris,
France,
2Aremis-aegisnet,
Neuilly
sur
Seine,
France
|
|
PCN31
|
A COST
MINIMISATION
ANALYSIS
OF
NAVELBINE-CISPLATIN
VERSUS
GEMCITABINE-CISPLATIN
IN
ADVANCED
NON-SMALL
CELL
LUNG
CANCER
IN
POLAND
|
|
|
Skowron
A,
Polak S,
Brandys
J |
|
|
Jagiellonian University, Cracow, Malopolska, Poland |
|
PCN32
|
COST-MINIMIZATION
ANALYSIS
OF ORAL
VS. IV
FLUDARABINE
FOR THE
TREATMENT
OF
B-CELL
CHRONIC
LYMPHOCYTIC
LEUKEMIA
(B-CLL)
IN
BRAZIL
|
|
|
Araujo G1, Fonseca M1, Bigni R2 |
|
|
1Axia.Bio
Consulting,
São
Paulo,
Brazil,
2INCA,
Rio de
Janeiro,
Brazil
|
|
PCN33
|
A
COST-CONSEQUENCE
ANALYSIS
OF
DARBEPOETIN
ALFA
ADMINISTERED
EVERY 3
WEEKS
(Q3W_DA)
COMPARED
TO
WEEKLY
EPOETIN
ALFA
(QW_EA)
OR
EPOETIN
BETA
(QW_EB)
IN
PATIENTS
WITH
CHEMOTHERAPY-INDUCED
ANEMIA
(CIA): A
RETROSPECTIVE
STUDY
|
|
|
Van
Bellinghen
LA1,
Demarteau
N1,
Annemans
L1,
Bracco A2 |
|
|
1IMS
HEOR,
Brussels,
Belgium,
2Amgen
(Europe)
GmbH,
Zug,
Switzerland
|
|
PCN34
|
EFFECT
OF
METASTASIS
LOCALIZATION
ON
SYMPTOMS
AND
ASSISTANCE
COSTS IN
ADVANCED
NSCLC
PATIENTS.
FURTHER
EVIDENCE
FROM THE
HABIT
STUDY.
|
|
|
Negrini
C1, Falcone A2 |
|
|
1Pbe
consulting,
Milano,
Italy,
2AstraZeneca,
Basiglio,
MI,
Italy
|
|
PCN35
|
BURDEN
OF
ILLNESS
OF RENAL
CELL
CARCINOMA
IN SPAIN
|
|
|
Maroto P1,
Villavicencio
H2,
Piñol C3,
Urruticoechea
L4 |
|
|
1Hospital
de la
Santa
Creu i
Sant
Pau,
Barcelona,
Spain,
2Fundació
Puigvert,
Barcelona,
Spain,
3Q.F.
Bayer,
S.A,
Barcelona,
Spain,
4Q.
F.
Bayer,
S.A,
Barcelona,
Spain
|
|
PCN36
|
BURDEN
OF
CERVICAL
CANCER
IN
POLAND.
|
|
|
Kawalec
P1, Glogowski C2, Krzyzanowska A3 |
|
|
1Centrum
HTA,
Krakow,
Poland,
2GSK
Commercial
Sp. z
o.o,
Warsaw,
Poland,
3GlaxoSmithKline
Poland,
Warsaw,
Poland
|
|
PCN37
|
COMPARING
MANAGEMENT
PATTERNS
AND
ASSOCIATED
COSTS
FOR
WOMEN
WITH
ABNORMAL
CERVICAL
CYTOLOGY
IN 5
DIFFERENT
COUNTRIES
|
|
|
Rash B1, Van Kriekinge G2 |
|
|
1Health
Market
International,
Ann
Arbor,
MI, USA,
2GlaxoSmithKline
Biologicals,
Rixensart,
Brabant,
Belgium
|
|
PCN38
|
'COST OF
ILLNESS'
ANALYSIS
OF RENAL
CELL
CARCINOMA
|
|
|
Lang K1, Danchenko N1, Gondek K2, Schwartz
B2,
Thompson
D1 |
|
|
1i3
Innovus,
Medford,
MA, USA,
2Bayer
Pharmaceuticals
Corporation,
West
Haven,
CT, USA
|
|
PCN39
|
COST-UTILITY
ANALYSIS
IN A
FRENCH
SETTING
OF
ADJUVANT
THERAPY
WITH
HERCEPTIN
IN
PATIENTS
WITH
HER-2
POSITIVE
BREAST
CANCER
|
|
|
Fagnani
F1, Colin X1, Arveux P2, Coudray-Omnès
C3 |
|
|
1Cemka-Eval,
BOURG-LA-REINE,
France,
2CLCC
Georges-François
Leclerc,
Dijon,
France,
3Roche,
Neuilly
sur
Seine,
France
|
|
PCN40
|
COST
EFFECTIVENESS
OF
RITUXIMAB
PLUS CVP
IN
PREVIOUSLY
UNTREATED
INDOLENT
NON-HODGKIN'S
LYMPHOMA
|
|
|
Maturi B1, Tong W2, Gyldmark M3, Creeden J3,
Aultman
R3,
Jost F3 |
|
|
1Hoffmann-La
Roche
Limited,
Mississauga,
ON,
Canada,
2McMaster
University,
Hamilton,
ON,
Canada,
3F.
Hoffmann-La
Roche
Ltd,
Basel,
Switzerland
|
|
PCN41
|
COST-EFFECTIVENESS
OF TAC
VERSUS
FAC FOR
THE
TREATMENT
OF NODE
POSITIVE
BREAST
CANCER
IN THE
ADJUVANT
SETTING
|
|
|
Fonseca
M1, Araujo G1, Saad E2, Uehara R3 |
|
|
1Axia.Bio
Consulting,
São
Paulo,
Brazil,
2Dendrix,
São
Paulo,
Brazil,
3Sanofi
Aventis,
São
Paulo,
Brazil
|
|
PCN42
|
COST
EFFECTIVENESS
OF
FULVESTRANT
AS AN
ADDITIONAL
ENDOCRINE
STEP IN
THE
TREATMENT
SEQUENCE
FOR
HORMONE
RESPONSIVE
ADVANCED
BREAST
CANCER
|
|
|
Hirsch M1, Gait C2, Chambers J2 |
|
|
1AstraZeneca
UK Ltd,
Macclesfield,
Cheshire,
UK,
2Mapi
Values
Ltd,
Macclesfield,
Cheshire,
UK
|
|
PCN43
|
COST-EFFECTIVENESS
OF
CETUXIMAB
(ERBITUX®)
IN
COMBINATION
WITH
RADIOTHERAPY
VERSUS
RADIOTHERAPY
ALONE IN
THE
TREATMENT
OF
LOCALLY
ADVANCED
HEAD AND
NECK
CANCER
IN
FRANCE
|
|
|
Brown B1,
Robinson
P1,
Launois
R2,
Griebsch
I3 |
|
|
1IMS
Health,
London,
UK,
2REES,
Paris,
France,
3Merck
KGaA,
Darmstadt,
Germany
|
|
PCN44
|
COST
UTILITY
ANALYSIS
OF
PRIMARY
PROPHYLAXIS
WITH
PEGFILGRASTIM
VERSUS
FILGRASTIM
FOR
BREAST
CANCER
IN THE
UK
|
|
|
Booth P1, Dubois R2, Doan QV2, Liu Z2 |
|
|
1Amgen
Ltd,
Cambridge,
UK,
2Cerner
Health
Insights,
Beverly
Hills,
CA, USA
|
|
PCN45
|
COST
EFFECTIVENESS
OF
ADDING
IMATINIB
TO
CHEMOTHERAPY
IN ADULT
PATIENTS
WITH
PHILADELPHIA
CHROMOSOME-POSITIVE
ACUTE
LYMPHOBLASTIC
LEUKEMIA
(PH+ALL):
AN
EXPLORATORY
ANALYSIS
FOR THE
UK
|
|
|
Botteman
MF,
Tran KT,
Stephens
JM |
|
|
PharMerit
North
America
LLC,
Bethesda,
MD, USA
|
|
PCN46
|
EPOIETIN
ALPHA
TREATMENT
FOR
CANCER
PATIENTS
WITH
CHEMOTHERAPY
INDUCED
ANAEMIA
- A
COST-EFFECTIVENESS
ANALYSIS
FOR
SWEDEN
|
|
|
Borg S,
Glenngård
AH,
Persson
U |
|
|
The
Swedish
Institute
for
Health
Economics,
IHE,
Lund,
Sweden
|
|
|
|
Health
Care Use
& Policy
Studies |
|
PCN47
|
COUNTY
LEVEL
INEQUALITIES
IN THE
ATTENDANCE
OF THE
HUNGARIAN
ORGANIZED
NATIONWIDE
CERVICAL
CANCER
SCREENING
PROGRAMME
|
|
|
Boncz I1,
Sebestyén
A1,
Döbrõssy
L2,
Budai A2,
Betlehem
J3,
Ember I3 |
|
|
1National
Health
Insurance
Fund
Administration
(OEP),
Budapest,
Hungary,
2National
Public
Health
and
Medical
Officers
Service
(ÁNTSZ),
Budapest,
Hungary,
3University
of Pécs,
Pécs,
Hungary
|
|
PCN48
|
A MODEL
FOR
PROJECTING
BOWEL
CANCER
INCIDENCE
AND
MORTALITY:
APPLICATION
TO THE
UK BOWEL
CANCER
SCREENING
PROGRAM.
|
|
|
Muston D1, Howard PA1, Lee DW2 |
|
|
1Heron
Evidence
Development
Ltd,
Letchworth,
Herts,
UK,
2GE
Healthcare,
Waukesha,
WI, USA
|
|
PCN49
|
FACTORS
INFLUENCING
INEQUITABLE
ACCESS
TO
RADIATION
THERAPY:
THE CASE
STUDY OF
CANCER
PATIENTS
IN
THAILAND
|
|
|
Prakongsai
P1,
Chunharas
S2,
Tangcharoensathien
V1 |
|
|
1International
Health
Policy
Program
-
Thailand,
Nonthaburi,
Thailand,
2National
Health
Foundation,
Bangkok,
Thailand
|
|
PCN50
|
BOWEL
CANCER
SCREENING.
BALANCING
COST-EFFECTIVENESS
AND
AFFORDABILITY.
|
|
|
Howard
PA1, Muston D1, Lee DW2 |
|
|
1Heron
Evidence
Development
Ltd,
Letchworth,
Herts,
UK,
2GE
Healthcare,
Waukesha,
WI, USA
|
|
PCN51
|
PHYSICIAN
AND
PATIENT
CHARACTERISTICS
ASSOCIATED
WITH
OUTPATIENT
BREAST
CANCER
SCREENING
RECOMMENDATIONS:
ANALYSIS
OF US
OUTPATIENT
DATA
1996-2004
|
|
|
Balkrishnan
R,
Bhosle
MJ |
|
|
The Ohio
State
University
College
of
Pharmacy,
Columbus,
OH, USA
|
|
PCN52
|
SCREENING
RATE IN
THE
HUNGARIAN
ORGANIZED
NATIONWIDE
CERVICAL
CANCER
SCREENING
PROGRAMME
|
|
|
Boncz I1,
Sebestyén
A1,
Döbrõssy
L2,
Budai A2,
Betlehem
J3,
Ember I3 |
|
|
1National
Health
Insurance
Fund
Administration
(OEP),
Budapest,
Hungary,
2National
Public
Health
and
Medical
Officers
Service
(ÁNTSZ),
Budapest,
Hungary,
3University
of Pécs,
Pécs,
Hungary
|
|
PCN53
|
AGE-GROUP
SPECIFIC
COVERAGE
OF THE
HUNGARIAN
ORGANIZED
NATIONWIDE
CERVICAL
CANCER
SCREENING
PROGRAMME
|
|
|
Boncz I1,
Sebestyén
A1,
Döbrõssy
L2,
Budai A2,
Betlehem
J3,
Ember I3 |
|
|
1National
Health
Insurance
Fund
Administration
(OEP),
Budapest,
Hungary,
2National
Public
Health
and
Medical
Officers
Service
(ÁNTSZ),
Budapest,
Hungary,
3University
of Pécs,
Pécs,
Hungary
|
|
|
|
Methods
&
Concepts |
|
PCN54
|
ESTIMATING
THE
CLINICAL
BENEFITS
OF
HPV-16/18
VACCINATION:
CHALLENGES
OF
MODELING
PREDICTED
CASES OF
CERVICAL
CANCER
IN
POLAND
AND
MEXICO,
TWO
COUNTRIES
WITH
DIFFERING
DEGREES
OF
CERVICAL
DISEASE
AND
POPULATION
STABILITY
|
|
|
Rogoza
RM1, Standaert B2 |
|
|
1i3
Innovus,
Burlington,
Ontario,
Canada,
2GlaxoSmithKline
Biologicals,
Rixensart,
Belgium
|
|
PCN55
|
LONG
TERM
CLINICAL
EFFECT
OF AN
HPV-VACCINE
FOR THE
PREVENTION
OF
CERVICAL
CANCER
IN
FRANCE
IN
RELATION
TO AGE
OF
VACCINATION:
RESULTS
FROM A
MARKOV
MODEL.
|
|
|
Demarteau
N1,
Detournay
B2,
El
Hasnaoui
A3,
Standaert
B4,
Annemans
L5 |
|
|
1IMS
HEOR,
Brussels,
Belgium,
2CEMKA-EVAL,
Bourg-la-Reine,
France,
3GlaxoSmithKline
France,
Marly-Le-Roi
Cedex,
France,
4GlaxoSmithKline
Biologicals,
Rixensart,
Belgium,
5Health
Economics
and
Outcomes
Research,
Brussels,
Belgium
|
|
PCN56
|
OUTCOME
VALIDATION
OF A
SUCCINCT
HPV
INFECTION
MODEL
FOR
FRANCE
|
|
|
Demarteau
N1,
Detournay
B2,
El
Hasnaoui
A3,
Standaert
B4,
Annemans
L5 |
|
|
1IMS
HEOR,
Brussels,
Belgium,
2CEMKA-EVAL,
Bourg-la-Reine,
France,
3GlaxoSmithKline
France,
Marly-Le-Roi
Cedex,
France,
4GlaxoSmithKline
Biologicals,
Rixensart,
Belgium,
5Health
Economics
and
Outcomes
Research,
Brussels,
Belgium
|
|
PCN57
|
TRASTUZUMAB
USE FOR
METASTATIC
BREAST
CANCER-
IS
"MEDIAN
TIME TO
TREATMENT
FAILURE"
AN
ACCURATE
PARAMETER
FOR
BUDGET
IMPACT
ANALYSIS?
|
|
|
Hammerman
A,
Klang
SH,
Liebermann
N |
|
|
Clalit
Health
Services,
Tel-Aviv,
Israel
|
|
PCN58
|
PRESCRIPTION
MEDICATION
COSTS TO
PROSTATE
CANCER
PATIENTS:
SURVEY
RESPONSES
COMPARED
TO AN
ADMINISTRATIVE
REGISTER
|
|
|
Booth N1, Rissanen P1, Tammela T2 |
|
|
1University
of
Tampere,
Tampere,
Finland,
2Tampere
University
Hospital,
Tampere,
Finland
|
|
PCN59
|
THE
ECONOMIC
VALUE OF
INNOVATIVE
TREATMENTS
OVER THE
PRODUCT
LIFE
CYCLE:
THE CASE
OF
TRASTUZUMAB
|
|
|
Garrison
LP,
Veenstra
DL |
|
|
University of Washington, Seattle, WA, USA |
|
PCN60
|
ASSESSMENT
OF THE
COMPUTATIONAL
INTELLIGENCE
BASED
MODELS
USEFULNESS
FOR
PHARMACOECONOMICS
NEEDS
|
|
|
Polak S1,
Skowron
A2,
Mendyk A1,
Brandys
J1 |
|
|
1Jagiellonian
University,
Cracow,
Malopolska,
Poland,
2Jagiellonian
University,
Cracow,
Poland
|
|
PCN61
|
Withdrawn |
|
|
|
|
PCN62
|
UTILITY
ELICITATION
IN
PATIENTS
WITH
FOLLICULAR
LYMPHOMA
|
|
|
Wild D1, Walker M2, Pettengell R3, Lewis G4 |
|
|
1Oxford
Outcomes
Ltd,
Oxford,
Oxfordshire,
UK,
2Roche
Products
Ltd,
Welwyn
Garden
City,
Herts,
UK,
3St
Georges
Hospital,
London,
UK,
4Roche
Products
Limited,
Welwyn
Garden
City, UK
|
|
PCN63
|
ADVANCED
CUTANEOUS
MALIGNANT
MELANOMA:
SYSTEMATIC
REVIEW
OF
PHARMACOECONOMIC
AND
QUALITY
OF LIFE
STUDIES
|
|
|
Machado
M1, Cashin R2, Lui P3, Hemels M4,
Corey-Lisle
P5,
Einarson
TR2 |
|
|
1Universidad
de
Chile,
Santiago,
RM,
Chile,
2University
of
Toronto,
Toronto,
ON,
Canada,
3University
of
Toronto,
M5S 2S2,
ON,
Canada,
4Bristol-Myers
Squibb,
Braine-L'Alleud,
Belgium,
5Bristol-Myers
Squibb,
Wallingford,
CT, USA
|
|
PCN64
|
DIFFERENTIAL
ITEM
FUNCTIONING
USING
RASCH
ANALYSIS
|
|
|
Brodersen
J1,
Thorsen
H2 |
|
|
1University
of
Copenhagen,
Copenhagen,
Denmark,
2Copenhagen
University,
Copenhagen,
Denmark
|
|
PCN65
|
Withdrawn |
|
|
|
|
|
|
PCN66
|
ADHERENCE
IN
CANCER
PATIENTS
RECEIVING
ORAL
CAPECITABINE
|
|
|
Roth S1, Simons S1, Arjukese A1, Braun M1,
Ko Y2,
Kuhn W1,
Mey U1,
Schwindt
P3,
Wolter H3,
Jaehde U1 |
|
|
1University
of Bonn,
Bonn,
NRW,
Germany,
2Johanniter
Hospital,
Bonn,
NRW,
Germany,
3Oncology
Practice,
Bonn,
NRW,
Germany
|
|
PCN67
|
PREVENTION
OF
CHEMOTHERAPY
INDUCED
NAUSEA
AND
VOMITING
WITH
5HT3
RECEPTOR
ANTAGONISTS
AND
HEALTH
RELATED
QOL
|
|
|
García
Pulgar
MS1,
Constenla
M2,
Montaño
A3,
García
Dominguez
R4,
Pérez
Manga G5,
Batista
N6,
Ordóñez
A7,
Montalar
J8,
Benavides
M9,
Ruíz MA10,
Garrido
J10,
Alvarez
Sanz C1 |
|
|
1Roche
Farma
S.A,
Madrid,
Spain,
2Complejo
Hospitalario
Provincial
de
Pontevedra,
Pontevedra,
Spain,
3Complejo
Hospitalario
Juan
Ramón
Jiménez,
Huelva,
Spain,
4Hospital
Universitario
de
Salamanca,
Salamanca,
Spain,
5Hospital
General
Universitario
Gregorio
Marañón,
Madrid,
Spain,
6Hospital
Universitario
de
Canarias,
La
Laguna,
Spain,
7Hospital
Universitario
La Paz,
Madrid,
Spain,
8Hospital
Universitario
La Fe,
Valencia,
Spain,
9Complejo
Hospitalario
Carlos
Haya,
Málaga,
Spain,
10Universidad
Autónoma
de
Madrid,
Madrid,
Spain
|
|
PCN68
|
QUALITY
OF LIFE
OF
PATIENTS
RECEIVING
ADJUVANT
CHEMOTHERAPIES
FOR
BREAST
CANCER
IN JAPAN
|
|
|
Fukuda T1, Shimozuma K2, Ohsumi S3, Mukai H4,
Morita S5,
Imai H6,
Watanabe
T7,
Ohashi Y1 |
|
|
1The
University
of
Tokyo,
Bunkyo,
Tokyo,
Japan,
2University
of
Marketing
and
Distribution
Sciences
/ Public
Health
Research
Foundation,
Kobe,
Hyogo,
Japan,
3Shikoku
Cancer
Center,
Matsuyama,
Ehime,
Japan,
4National
Cancer
Center,
Kashiwa,
Chiba,
Japan,
5Kyoto
University,
Kyoto,
Kyoto,
Japan,
6National
Institute
of
Public
Health,
Wako,
Saitama,
Japan,
7Hamamatsu
Oncology
Center,
Hamamatsu,
Shizuoka,
Japan
|
|
PCN69
|
HEALTH
UTILITIES
IN THE
UK FOR
SECOND
LINE
ADVANCED
NON-SMALL
CELL
LUNG
CANCER
(NSCLC)
FOLLOWING
PRIOR
CHEMOTHERAPY
|
|
|
Nafees B1, Stafford MR1, Bhalla S2, Watkins J3 |
|
|
1UBC,
London,
UK,
2Lilly
UK,
Bassingstoke,
UK,
3Lilly
UK,
Basingstoke,
UK
|
|
PCN70
|
RELIABILITY
AND
VALIDITY
OF
HEALTH
UTILITIES
INDEX
(HUI)
SCORES
FOR
SURVIVORS
OF BRAIN
TUMORS
IN
CHILDHOOD:
AGREEMENT
BETWEEN
PATIENTS
AND
PARENTS
|
|
|
Horsman
JR1,
Spitzer
R2,
Hsu T1,
Duckworth
J3,
Barr RD1,
Furlong
W1 |
|
|
1McMaster
University,
Hamilton,
ON,
Canada,
2University
of
Toronto,
Toronto,
ON,
Canada,
3McMaster
Children's
Hospital,
Hamilton,
ON,
Canada
|
|
PCN71
|
PSYCHOMETRIC
EVALUATION
OF A
PATIENT
REPORTED
OUTCOME
QUESTIONNAIRE
FOR
METASTATIC
COLORECTAL
CANCER
|
|
|
Colwell
HH1,
Pritchard
ML1,
Mathias
SD1,
Lu ZJ2,
Wright N3 |
|
|
1Ovation
Research
Group,
San
Francisco,
CA, USA,
2Amgen,
Inc,
Thousand
Oaks,
CA, USA,
3Amgen,
Inc,
Cambridge,
England
|
|
PCN72
|
A
COMPARISON
OF
PATIENT
REPORTED
OUTCOMES
ACROSS
CURATIVE
TREATMENTS
OF
ELDERLY
PROSTATE
CANCER
PATIENTS
|
|
|
Jayadevappa
R,
Chhatre
S, Wein
AJ,
Malkowicz
SB |
|
|
University of Pennsylvania, Philadelphia, PA, USA |
|
PCN73
|
VARIATIONS
IN
SATISFACTION
WITH
CARE AND
EMOTIONAL
WELL-BEING
OF
EARLY-STAGE
PROSTATE
CANCER
PATIENTS
|
|
|
Jayadevappa
R1,
Chhatre
S1,
Wein AJ2,
Malkowicz
SB1 |
|
|
1University
of
Pennsylvania,
Philadelphia,
PA, USA,
2University
of
Pennsylvania,
Phildelphia,
PA, USA
|
|
PCN74
|
UTILITIES
ASSOCIATED
WITH
NON-SMALL
CELL
LUNG
CANCER
(NSCLC):
A
COMMUNITY
STUDY
|
|
|
Tabberer
M1,
Stamuli
E1,
Walker M2,
Summerhayes
M2,
Lees M1 |
|
|
1Oxford
Outcomes
Ltd,
Oxford,
Oxon,
UK,
2Roche
Products
Ltd,
Welwyn
Garden
City,
Herts,
UK
|
|
|
|
INFECTION
|
|
Cost
Studies |
|
PIN1
|
CLINICAL
AND
ECONOMIC
IMPACT
OF
INTRODUCING
A
QUADRIVALENT
(6, 11,
16, 18)
HUMAN
PAPILLOMAVIRUS
VACCINE
IN
SWITZERLAND
|
|
|
Gerber S1,
Heinzl S2,
Largeron
N3,
Bénard S4 |
|
|
1CHUV,
Lausanne,
Switzerland,
2Kantonsspital,
Bruderholz,
Switzerland,
3sanofi
pasteur
MSD,
Lyon,
France,
4st[è]ve
consultants,
Lyon,
France
|
|
PIN2
|
A
COST-BENEFIT
ANALYSIS
OF
DIFFERENT
VARICELLA
VACCINATION
STRATEGIES
INVOLVING
ITALIAN
CHILDREN
AND
ADOLESCENTS
|
|
|
Marocco
A1, Bamfi F1, Banz K2, Boccalini S3,
Bechini
A3,
Bonanni
P3 |
|
|
1GlaxoSmithKline
Spa,
Verona,
Veneto,
Italy,
2Outcomes
International,
Basel,
Switzerland,
3University
of
Florence,
Florence,
Italy
|
|
PIN3
|
COST –
EFFECTIVNESS
ANALYSIS
OF
TONSILOPHARYNGITIS
AND
RHYNOPHARINGITIS
ACCUTA,
ANTIBIOTIC
TREATMANT,
SRBIJA,
NIS
REGION
|
|
|
Mihajlovic
MM1,
Nikolic
S2 |
|
|
1City
Pharmacy
Nis,
Nis,
Yugoslavia,
2Government
Primary
Health
Care
Institution,
Nis,
Serbia,
Serbia
and
Montenegro
|
|
PIN4
|
ANTIBIOTIC
THERAPY
OF
NOSOCOMIAL
INFECTION
IN THE
INTENSIVE
CARE
UNIT: A
COST-EFFECTIVENESS
ANALYSIS
|
|
|
Kulikov
A,
Krysanov
I,
Lomakin
A |
|
|
Moscow Medical Academy, Moscow, Russia |
|
PIN5
|
THE COST
EFFECTIVENESS
ANALYSIS
OF
TREATMENT
WITH
PEGINTERFERON
ALFA-2A
(40KD)
IN
PATIENTS
WITH
HBEAG-NEGATIVE
CHRONIC
HEPATITIS
B
|
|
|
Kowalik
E1, Niewada M2, Jakubczyk M3, Horban A4,
Berak H4,
Szkultecka-Debek
M5 |
|
|
1Institute
of
Cardiology,
Warsaw,
Poland,
2Medical
University
of
Warsaw,
Warsaw,
Poland,
3Warsaw
School
of
Economics,
Warsaw,
Poland,
4Regional
Hospital
of
Infectious
Diseases,
Warsaw,
Poland,
5Roche
Polska
Sp. z
o.o,
Warsaw,
Poland
|
|
PIN6
|
PRIMARY
PROPHYLAXIS
AGAINST
FEBRILE
NEUTROPENIA
WITH
PEGFILGRASTIM
IS MORE
COST-EFFECTIVE
THAN
FILGRASTIM
IN WOMEN
WITH
BREAST
CANCER
RECEIVING
CHEMOTHERAPY
IN
GERMANY
|
|
|
Goertz A1, Dubois R2, Doan QV2, Liu Z2,
Heissel
A3,
Von
Minckwitz
G4 |
|
|
1Amgen
Germany
GmbH,
Munich,
Germany,
2Cerner
Health
Insights,
Beverly
Hills,
CA, USA,
3Amgen
Europe,
Zug,
Switzerland,
4Universitäts-Frauenklinik
Frankfurt,
Frankfurt,
Germany
|
|
PIN7
|
Withdrawn |
|
PIN8
|
COST-EFFECTIVENESS
OF
INTERVENTIONS
ENSURING
BLOOD
TRANSFUSION
SAFETY
IN
AFRICA
|
|
|
van
Hulst M1,
Dhingra-Kumar
N2,
Van der
Schaaf
IP3,
Smit
Sibinga
CT4,
Postma
MJ5 |
|
|
1Groningen
University
Institute
for Drug
Exploration
/
Martini
Hospital,
Groningen,
The
Netherlands
Antilles,
2WHO,
Geneva,
Switzerland,
3VU,
Amsterdam,
The
Netherlands,
4Sanquin
Consulting
Services,
Groningen,
The
Netherlands,
5University
of
Groningen
/
Groningen
University
Institute
for Drug
Exploration
(GUIDE),
Groningen,
Groningen,
The
Netherlands
|
|
PIN9
|
COST-EFFECTIVENESS
ANALYSIS
OF
COMBINED
THERAPY
WITH
PEGINTERFERON
ALFA-2A
(40KD)
(PEGASYS)
AND
RIBAVIRIN
(
COPEGUS)
IN
PATIENTS
WITH
CHRONIC
C
HEPATITIS
(CHC)
AND
HUMAN
IMMUNODEFICIENCY
VIRUS (
HIV)
CO-INFECTION
|
|
|
Rubio
Terres C1,
Alvarez
Sanz C2,
Patel K3 |
|
|
1Hero
Consulting,
Madrid,
Madrid,
Spain,
2Roche
Farma,
Madrid,
Spain,
3Hoffman-La
Roche
Inc,
Nutley,
NJ, USA
|
|
PIN10
|
COST-EFFECTIVENESS
OF
PEGINTERFERON
ALFA-2A
(40KD)
FOR THE
TREATMENT
OF
CHRONIC
HEPATITIS
B IN
ITALY
|
|
|
Eandi M1,
Iannazzo
S2,
Pradelli
L2,
Patel K3,
Giuliani
G4 |
|
|
1Università
di
Torino,
Turin,
Italy,
2Advanced
Research
Srl,
Turin,
Italy,
3Hoffmann-La
Roche
Inc,
Nutley,
NJ, USA,
4Roche
S.p.A,
Milano,
Italy
|
|
PIN11
|
COST-EFFECTIVENESS
OF
OSELTAMIVIR
FOR THE
TREATMENT
OF
INFLUENZA
IN
ADULTS
AND
CHILDREN
IN
FINLAND
|
|
|
Järvinen
A1,
Joutseno
J2,
Gyldmark
M3 |
|
|
1Helsinki
University
Hospital,
Helsinki,
Finland,
2Roche
Oy,
Espoo,
Finland,
3F
Hoffmann
La
Roche,
Basel,
Switzerland
|
|
PIN12
|
COST
MINIMALISATION
ANALYSIS
OF
AVERAGE
ACUTE
HOSPITAL
INFECTIONS
TREATMENT
WITH
TARGOCID
(TEICOPLANIN)
OR
VANCOMYCINE
FROM
SERVICE-PROVIDER
PERSPECTIVE
IN
POLAND
|
|
|
Kawalec
P1, Lis J2 |
|
|
1Centrum
HTA,
Krakow,
Poland,
2Sanofi-Aventis,
Warsaw,
Poland
|
|
|
|
PIN13
|
ECONOMIC
EVALUATION
OF EARLY
MONOTHERAPY
WITH
INTERFERON
VERSUS
DELAYED
COMBINATION
THERAPY
WITH
INTERFERON
AND
RIBAVIRIN
IN
PATIENTS
WITH
ACUTE
HEPATITIS
C
|
|
|
Dintsios
CM1,
Haverkamp
A2,
Krauth C2 |
|
|
1Institute
for
Quality
and
Efficiency
in
Health
Care
(IQWiG),
Cologne,
Germany,
2Hannover
Medical
School,
Hannover,
Germany
|
|
PIN14
|
ECONOMIC
EVALUATION
OF
CASPOFUNGIN
(CANCIDAS®)
VERSUS
LIPOSOMAL
AMPHOTERICIN
B FOR
EMPIRICAL
THERAPY
OF
SUSPECTED
SYSTEMIC
FUNGAL
INFECTION
IN THE
GERMAN
HOSPITAL
SETTING
|
|
|
Kaskel P1, Tuschy S2, Wagner A1, Bannert C3,
Cornely
OA4,
Glasmacher
A2,
Lütkes P5,
Lipp HP6,
Ullmann
AJ7 |
|
|
1MSD
Sharp &
Dohme
GmbH,
Haar,
Germany,
2Bonn
University
Hospital,
Bonn,
Germany,
3Augsburg
Academic
Hospital,
Augsburg,
Germany,
4Cologne
University
Hospital,
Köln,
Germany,
5Essen
University
Hospital,
Essen,
Germany,
6Tubingen
University
and
University
Hospital,
Tübingen,
Germany,
7Johannes
Gutenberg-University
Mainz,
Mainz,
Germany
|
|
PIN15
|
CHRONIC
HEPATITIS
B (CHB)
MANAGEMENT
COSTS IN
SWEDEN
|
|
|
De Cock
E1,
Dale P1,
Cerri KH2,
Zammit D2,
Flamholc
L3 |
|
|
1United
Biosource,
London,
England,
UK,
2Bristol-Myers
Squibb,
Braine
l'Alleud,
Wallonie,
Belgium,
3Dept
of
Infectious
Diseases,
Malmo,
Sweden
|
|
PIN16
|
AN
OBSERVATIONAL
HEALTH-ECONOMIC
ANALYSIS
OF THE
TREATMENT
OF
PATIENTS
WITH
VORICONAZOLE
IN A
REAL
LIFE
SETTING
|
|
|
Van
Campenhout
H1,
De Mees
V1,
Marbaix
S1,
Annemans
L2 |
|
|
1Pfizer,
Brussels,
Belgium,
2Health
Economics
and
Outcomes
Research,
Brussels,
Belgium
|
|
PIN17
|
THE
COST-EFFECTIVENESS
OF A
MENINGOCOCCAL
SEROGROUP
C
CONJUGATE
VACCINE
IN
GERMANY
|
|
|
Carroll
SM1,
Scott DA1,
Sidhu MK1,
Runge C2 |
|
|
1Fourth
Hurdle
Consulting,
London,
UK,
2Wyeth
Pharma
GmbH,
Muenster,
Germany
|
|
PIN18
|
COST-UTILITY
ANALYSIS
OF
TREATMENT
ALTERNATIVES
IN
PATIENTS
WITH
HBEAG
POSITIVE
CHRONIC
HEPATITIS
B
|
|
|
Sun X1, Li Y2, Zhao L3 |
|
|
1Department
of
Clinical
Epidemiology
and
Evidence-based
Medicine,
West
China
Hospital,
Sichuan
University,
Chengdu,
China,
2West
China
Hospital,
Sichuan
University,
Chengdu,
China,
3Center
of
Infectious
Diseases,
West
China
Hospital,
Sichuan
University,
Chengdu,
China
|
|
PIN19
|
COST-EFFECTIVENESS
OF MASS
VACCINATION
WITH A
ROTAVIRUS
VACCINE
IN THE
NETHERLANDS
|
|
|
Al MJ1, Goossens L1, Hövels AM2, Michielsen
CP2,
Standaert
BA3 |
|
|
1Erasmus
MC,
Rotterdam,
The
Netherlands,
2GlaxoSmithKline
The
Netherlands,
Zeist,
The
Netherlands,
3GlaxoSmithKline
Biologicals,
Rixensart,
Belgium
|
|
PIN20
|
COSTS
AND
OUTCOMES
OF
NOSOCOMIAL
PNEUMONIA
IN A
SAMPLE
OF
BELGIAN
HOSPITALS
|
|
|
Spaepen
E1,
Merchant
S2,
Neslusan
C2,
Annemans
L3 |
|
|
1IMS
Health,
Brussels,
BRUSSELS,
Belgium,
2Johnson
and
Johnson
Pharmaceutical
Services,
L.L.C,
Raritan,
NJ, USA,
3Health
Economics
and
Outcomes
Research,
Brussels,
Belgium
|
|
|
|
Health
Care Use
& Policy
Studies |
|
PIN21
|
COST-BENEFIT
ANALYSIS
OF
VACCINATION
PROGRAMME
AGAINST
POLIOMYELITIS
IN
MALAYSIA:
ORAL
POLIO
VACCINE
(OPV) VS
INACTIVATED
POLIO
VACCINE
(IPV)
|
|
|
Aljunid
S |
|
|
National
University
of
Malaysia,
Kuala
Lumpur,
Malaysia
|
|
PIN22
|
TREATMENT
PATTERNS
AND
OUTCOMES
ASSOCIATED
WITH
MULTIDRUG
RESISTANT
STAPHYLOCOCCUS
AUREUS
INFECTIONS
(MRSA)
IN
CANADIAN
TEACHING
HOSPITALS:
INTERIM
ANALYSIS
|
|
|
Iskedjian
M1,
Machado
M2,
Costei A1,
Vicente
C3,
Han D3,
Einarson
TR2,
Piwko C1 |
|
|
1PharmIdeas
Research
and
Consulting
Inc,
Oakville,
ON,
Canada,
2University
of
Toronto,
Toronto,
ON,
Canada,
3Wyeth
Pharmaceuticals,
Markham,
ON,
Canada
|
|
PIN23
|
INDICATOR
OF
ANTIBIOTIC
USE IN
PUBLIC
PHARMACY
CHAIN
BELGRADE
|
|
|
Sovtic
DD1, Tasic L2, Stojanovic S1 |
|
|
1Pharmacy
Institution
Belgrade,
Belgrade,
Serbia
and
Montenegro,
2Faculty
of
pharmacy,
University
of
Belgrade,
Belgrade,
Serbia
and
Montenegro
|
|
PIN24
|
THE USE
OF
ANTIBIOTICS
IN
CHILDREN
POPULATION
IN
BELGRADE
REGION
|
|
|
Sovtic
DD1, Tasic L2, Stojanovic S1 |
|
|
1Pharmacy
Institution
Belgrade,
Belgrade,
Serbia
and
Montenegro,
2University
of
Belgrade,
Belgrade,
Serbia
and
Montenegro
|
|
PIN25
|
LONG
TERM
EFFECT
OF WARD
PHARMACY
CONTROLLED
ADMINISTRATION
OF
ANTIBIOTICS
ON
ANTIMICROBIAL
TREATMENT
COSTS
|
|
|
Van
Hulst M1,
Dekens
KG2,
Vogels
WHM3,
Postma
MJ4,
Visser T2 |
|
|
1Martini
Hospital
/ GUIDE,
Groningen,
The
Netherlands,
2Martini
Hospital,
Groningen,
The
Netherlands,
3Martini
Hospital
/
Laboratory
for
Infectious
Diseases,
Groningen,
The
Netherlands,
4University
of
Groningen
/
Groningen
University
Institute
for Drug
Exploration
(GUIDE),
Groningen,
Groningen,
The
Netherlands
|
|
PIN26
|
Withdrawn |
|
|
|
|
PIN27
|
ECONOMIC
MODELLING
TO
DETERMINE
THE
COST-EFFECTIVENESS
OF
TREATMENT
OF
PATIENTS
WITH
HISTOLOGICALLY
MILD
CHRONIC
HEPATITIS
C WITH
PEGYLATED
INTERFERON
ALPHA-2B
PLUS
RIBAVIRIN
|
|
|
Campbell
S1, Norris S1, Mernagh P1, Batey R2,
Dore GJ3 |
|
|
1Health
Technology
Analysts
Pty Ltd,
Balmain,
NSW,
Australia,
2Drug
and
Alcohol
Clinical
Services,
Hunter
New
England
Area
Health
Service,
Wallsend,
NSW,
Australia,
3Viral
Hepatitis
Clinical
Research
Program,
National
Centre
in HIV
Epidemiology
and
Clinical
Research,
Darlinghurst,
NSW,
Australia
|
|
PIN28
|
IS THE
PRESCRIBING
OF
ANTIBIOTICS
FOR THE
MOST
COMMON
INFECTIONS
IN
PRIMARY
HEALTH
CARE
RATIONAL
OR NOT?
|
|
|
Duborija-Kovacevic
N1,
Glomazic
Z2,
Goranovic
S3,
Tomic Z4 |
|
|
1University
of
Montenegro
Medical
School,
Podgorica,
Serbia
and
Montenegro,
2The
Republic
Health
Insurance
Fund of
Montenegro,
Podgorica,
Serbia
and
Montenegro,
3Medical
School
of the
University
of
Montenegro,
Podgorica,
Serbia
and
Montenegro,
4Medical
School
of the
University
in Novi
Sad,
Novi
Sad,
Serbia
and
Montenegro
|
|
|
|
Methods
&
Concepts |
|
PIN29
|
Withdrawn |
|
|
|
|
PIN30
|
PSYCHOMETRIC
VALIDATION
OF THE
ACTIVITY
IMPAIRMENT
ASSESSMENT
(AIA)
QUESTIONNAIRE
IN
PATIENTS
WITH
ACUTE
BACTERIAL
SINUSITIS.
|
|
|
Wild D1, Reaney MD1, Donatti C1, Keating K2 |
|
|
1Oxford
Outcomes
Ltd,
Oxford,
Oxfordshire,
UK,
2Bayer
HealthCare
Pharmaceuticals,
West
Haven,
CT, USA
|
|
Patient
Reported
Outcomes |
|
PIN31
|
HEALTH
RELATED
QUALITY
OF LIFE
IN
CHRONIC
HEPATITIS
B
PATIENTS
|
|
|
Li SC1, Ong SC2, Lim SG3 |
|
|
1National
University
of
Singapore,
Singapore,
Singapore,
2National
University
of
Singapore,
Singapore,
Singapore,
Singapore,
3National
University
of
Singapore,
National
University
Hospital,
Singapore,
Singapore,
Singapore
|
|
PIN32
|
VALIDATION
OF THE
PATIENTS'
ATTITUDES
AND
PERCEPTIONS
TOWARDS
HAART
QUESTIONNAIRE
|
|
|
Fumaz C1,
Knobel H2,
Segador
A3,
Lorenzo
A4,
González
J4,
García
Pulgar M5,
Badia X6,
Perulero
N6 |
|
|
1Hospital
Germans
Trias i
Pujol,
Badalona,
Barcelona,
Spain,
2Hospital
del Mar,
Barcelona,
Spain,
3Hospital
Reina
Sofía,
Córdoba,
Spain,
4Hospital
La Paz,
Madrid,
Spain,
5Roche
Farma,
Madrid,
Spain,
6Health
Outcomes
Research
Europe,
Barcelona,
Spain
|
|
|
|
MENTAL
HEALTH
|
|
Clinical
Outcomes
Studies |
|
PMH1 |
COST-EFFECTIVENESS
OF
CLINICALLY
PROVEN
TREATMENT
STRATEGIES
FOR
ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER
(ADHD):
IMPACT
OF
COEXISTING
CONDITIONS
|
|
|
Schlander
M1,
Schwarz
O1,
Foster
EM2,
Hakkaart-van
Roijen L3,
Jensen
PS4,
Persson
U5,
Santosh
PJ6,
Trott GE7,
MTA
Cooperative
Group O8 |
|
|
1Institute
for
Innovation
&
Valuation
in
Health
Care
(InnoVal-HC),
Eschborn,
Germany,
2University
of North
Carolina,
Chapel
Hill,
NC, USA,
3Institute
for
Medical
Technology
Assessment
(iMTA),
Rotterdam,
The
Netherlands,
4Columbia
University,
New
York,
NY, USA,
5The
Swedish
Institute
for
Health
conomics,
IHE,
Lund,
Sweden,
6Institute
of Child
Health -
Great
Ormond
Street
Hospital,
London,
UK,
7University
of
Wuerzburg,
Aschaffenburg,
Germany,
8National
Institutes
of
Mental
Health,
Bethesda,
MD, USA
|
|
PMH2
|
PREVALENCE
OF
METABOLIC
SYNDROME
IN
PATIENTS
WITH
BIPOLAR
DISORDER:
A CROSS-
SECTIONAL
ASSESSMENT
OF A
HEALTH
MANAGEMENT
ORGANIZATION
IN SPAIN
|
|
|
Sicras A1, Rejas J2, Navarro R1, Serrat J1,
Blanca M1 |
|
|
1Badalona
Serveis
Assistencials,
Badalona,
Barcelona,
Spain,
2Pfizer
Spain,
Alcobendas,
Madrid,
Spain
|
|
PMH3
|
PREVALENCE
AND
COMORBIDITY
BURDEN
IN
PATIENTS
WITH
BIPOLAR
DISORDERS:
CROSS-SECTIONAL
ANALYSIS
OF A
HEALTH
-PROVIDER
ADMINISTRATIVE
CLAIM
DATABASE
|
|
|
Sicras A1, Rejas J2, Navarro R1, Serrat J1,
Blanca M1 |
|
|
1Badalona
Serveis
Assistencials,
Badalona,
Barcelona,
Spain,
2Pfizer
Spain,
Alcobendas,
Madrid,
Spain
|
|
PMH4
|
ASSOCIATION
BETWEEN
CHANGES
ON THE
NEGATIVE
SYMPTOM
ASSESSMENT
SCALE
AND
MEASUREES
OF
FUNCTIONAL
OUTCOME
IN
SCHIZOPHRENIA
|
|
|
Leeuwenkamp
O1,
Velligan
D2,
Wang M2,
Haig G3,
Lancaster
S3,
Taylor T4,
Alphs L3 |
|
|
1Organon
International,
Molenstraat,
Oss, The
Netherlands,
2University
of
Texas,
San
Antonio,
TX, USA,
3Pfizer
Inc, Ann
Arbor,
MI, USA,
4Pfizer,
Ann
Arbor,
MI, USA
|
|
PMH5
|
A
3-MONTH
ASSESSMENT
OF
TREATMENT
PRESCRIBED
TO
PATIENTS
WITH
ADHD
AND
ITS
IMPACT
ON
CLINICAL
SEVERITY
AND
QOL
OUTCOMES
ACROSS
10
EUROPEAN
COUNTRIES.
RESULTS
FROM
ATTENTION
DEFICIT/
HYPERACTIVITY
DISODER
OBSERVATIONAL
RESEARCH
IN
EUROPE
(ADORE)
|
|
|
Mata
Lorenzo
MJ1
, Poole
L1,
Spiel
G2,
Dalsgaard
S3,
Falissard
B4,
Le
Heuzey
MF5,
Rothenberger
A6,
Dopfner
M7,
Baldursson
G8,
Curatolo
P9,
Pereira
RR10,
Vlasveld
L11,
Nøvik
T12,
Hervas
A13,
Preuss
U14,
Steinhausen
HC15,
Rasmussen
P16,
Coghill
D17,
Riley
AW18,
19Forrest
CB
|
|
|
1Eli
Lilly
&
Company
Limited,
Windlesham,
United
Kingdom,
2Landeskrankenhaus
Klagenfurt,
Klagenfurt,
Austria,
3Psykiatric
Hospital
for
Children
and
Adoloscents,
Risskov,
Denmark,
4Hôpital
Paul
Brousse,
Paris,
France,
5Hopital
Robert
Debré,
Paris,
France,
6Georg-August-Universität
Göttingen,
Göttingen,
Germany,
7Klilnik
und
Poliklinik
fur
Psychiatrie
und
Psychotherapie,
Köln,
Germany,
Landspitali
University
Hospital8,
Reykjavik,
Iceland,
9Clinica
Sant’Alessandro,
Rome,
Italy,
10Medisch
Centrum
Rijnmond-Zuid,
Rotterdam,
The
Netherlands,
11Reinier
de
Graaf
Gasthuis,
Delft,
The
Netherlands,
12BUPA-Poliklinisk
enhet,
Drammen,
Norway,
13CAP
Rambla,
Barcelona,
Spain,
14Kinder-u.
Jugendpsych.Poliklinik,
Bern,
Switzerland,
15FMH
Kinder-u.Jugendpsychiatrie,
Zurich,
Switzerland,
16BNK,
Göteborg,
Sweden,
17Centre
for
Child
Health,
Dundee,
UK,
18Baltimore,
USA,
Johns
Hopkins
Bloomberg
School
of
Public
Health,
Baltimore,
USA
|
|
PMH6
|
MENTAL
HEALTH
IN THE
FIRST
MONTHS
OF
HEMODIALYSIS
AS A
PREDICTOR
OF
SURVIVAL
|
|
|
Valdés C1, García Mendoza M1, Rebollo P2,
Ortega F1 |
|
|
1Hospital
Universitario
Central
de
Asturias,
Oviedo,
Asturias,
Spain,
2BAP
Health
Outcomes,
Oviedo,
Asturias,
Spain
|
|
|
|
Cost
Studies |
|
PMH7
|
OFF-LABEL
UTILIZATION
OF
METHYLPHENIDATE
FOR
ADULTS
WITH
ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER
(ADHD)
IN
GERMANY:
INSIGHTS
FROM THE
NORDBADEN
PROJECT
|
|
|
Schlander
M1,
Schwarz
O1,
Viapiano
M2,
Bonauer
N2 |
|
|
1Institute
for
Innovation
&
Valuation
in
Health
Care
(InnoVal-HC),
Eschborn,
Germany,
2Kassenaerztliche
Vereinigung
Baden-Wuerttemberg,
Karlsruhe,
Germany
|
|
PMH8
|
BUDGET
IMPACT
MODEL
FOR
DETERMINING
THE
COSTS OF
INTRODUCING
ZIPRASIDONE
FOR THE
MANAGEMENT
OF ACUTE
BIPOLAR
MANIA IN
SPAIN
|
|
|
Darba J1, Restovic G1, Rejas J2 |
|
|
1Universitat
de
Barcelona,
Barcelona,
Spain,
2Pfizer
Spain,
Alcobendas,
Madrid,
Spain
|
|
PMH9
|
COST-EFFECTIVENESS
OF
CLINICALLY
PROVEN
TREATMENT
STRATEGIES
FOR
ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER
(ADHD)
IN FIVE
JURISDICTIONS
|
|
|
Schlander
M1,
Schwarz
O1,
Hakkaart-van
Roijen L2,
Jensen
PS3,
Persson
U4,
Santosh
PJ5,
Trott GE6,
MTA
Cooperative
Group O7 |
|
|
1Institute
for
Innovation
&
Valuation
in
Health
Care
(InnoVal-HC),
Eschborn,
Germany,
2Institute
for
Medical
Technology
Assessment
(iMTA),
Rotterdam,
The
Netherlands,
3Columbia
University,
New
York,
NY, USA,
4The
Swedish
Institute
for
Health
conomics,
IHE,
Lund,
Sweden,
5Institute
of Child
Health -
Great
Ormond
Street
Hospital,
London,
UK,
6University
of
Wuerzburg,
Aschaffenburg,
Germany,
7National
Institutes
of
Mental
Health,
Bethesda,
MD, USA
|
|
PMH10
|
FUNCTIONAL
IMPAIRMENT
OF
PATIENTS
WITH
ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER
(ADHD):
AN
ALTERNATIVE
COST-EFFECTIVENESS
ANALYSIS
OF
CLINICALLY
PROVEN
TREATMENT
STRATEGIES
BASED
UPON THE
NIMH MTA
STUDY
|
|
|
Schlander
M1,
Schwarz
O1,
Hakkaart-van
Roijen L2,
Jensen
PS3,
Persson
U4,
Santosh
PJ5,
Trott GE6,
MTA
Cooperative
Group O7 |
|
|
1Institute
for
Innovation
&
Valuation
in
Health
Care
(InnoVal-HC),
Eschborn,
Germany,
2Institute
for
Medical
Technology
Assessment
(iMTA),
Rotterdam,
The
Netherlands,
3Columbia
University,
New
York,
NY, USA,
4The
Swedish
Institute
for
Health
conomics,
IHE,
Lund,
Sweden,
5Institute
of Child
Health -
Great
Ormond
Street
Hospital,
London,
UK,
6University
of
Wuerzburg,
Aschaffenburg,
Germany,
7National
Institutes
of
Mental
Health,
Bethesda,
MD, USA
|
|
PMH11
|
RATIONAL
CHOICE
OF
TREATMENT
STRATEGY
IN
MODERATE
TO
SEVERE
ALZHEIMER'S
DISEASE
PATIENTS
LIVING
IN
CANADA
|
|
|
Gagnon M1,
Rive B2,
Hux M3,
Cochran
J2,
Guilhaume
C2 |
|
|
1McMaster
University,
Hamilton,
ON,
Canada,
2Lundbeck
SAS,
Paris,
France,
3Innovus
Research
Inc,
Burlington,
ON,
Canada
|
|
PMH12
|
PHARMACOECONOMIC
ANALYSIS
OF
ANTIDEPRESSANTS
IN
BRAZIL
|
|
|
Machado
M1, Iskedjian M2, Ruiz I1, Einarson TR3 |
|
|
1Facultad
de
Ciencias
Quimicas
y
Farmaceuticas,
Universidad
de
Chile,
Santiago,
RM,
Chile,
2PharmIdeas
Research
and
Consulting
Inc,
Oakville,
ON,
Canada,
3University
of
Toronto,
Toronto,
ON,
Canada
|
|
PMH13
|
COST-EFFECTIVENESS
OF
ESCITALOPRAM
VERSUS
CITALOPRAM
IN
OUTPATIENTS
SUFFERING
FROM
MAJOR
DEPRESSIVE
DISORDER
|
|
|
Fantino
B1, Moore N2 |
|
|
1ADIM-AGORAS,
Lyon,
France,
2Victor
Segalen
University,
Bordeaux
Cedex,
France
|
|
PMH14
|
PHARMACOECONOMIC
POSITIONING
OF
SERTINDOLE
AMONG
ANTIPSYCHOTICS
IN THE
MANAGEMENT
OF
SCHIZOPHRENIA:
THE
HUNGARIAN
EXPERIENCE
|
|
|
Hansen K1, Bitter I2, Launois R3, Sapin C4 |
|
|
1H.
Lundbeck
A/S,
Paris,
France,
2Semmelweis
University,
Budapest,
Hungary,
3REES,
Paris,
France,
4Lundbeck
SAS,
Paris,
France
|
|
PMH15
|
COST-EFFECTIVENESS
OF
AMISULPRID
COMPARED
TO
RISPERIDONE
AND
OLANZAPINE
IN THE
TREATMENT
OF
SCHIZOPHRENIA
IN
POLAND
|
|
|
Kowalik
E1, Jakubczyk M2, Lis J3, Niewada M4 |
|
|
1Institute
of
Cardiology,
Warsaw,
Poland,
2Warsaw
School
of
Economics,
Warsaw,
Poland,
3Sanofi-Aventis,
Warsaw,
Poland,
4Medical
University
of
Warsaw,
Warsaw,
Poland
|
|
PMH16
|
COST
EFFECTIVENESS
MODEL
COMPARING
FAST
DISSOLVING
OLANZAPINE
AND
CONVENTIONAL
OLANZAPINE
TABLETS
IN THE
TREATMENT
OF
SCHIZOPHRENIA
|
|
|
Ozsogut
B1, Saylan M2 |
|
|
1Yeditepe
University
Faculty
of
Pharmacy,
Istanbul,
Turkey,
2Eli
Lilly
and
Company,
Istanbul,
Turkey
|
|
PMH17
|
COST-EFFECTIVENESS
OF LONG
ACTING
METHYLPHENIDATE-OROS
IN ADHD
YOUTHS
WITH
SUBOPTIMAL
SYMPTOM
CONTROL
ON
IMMEDIATE-RELEASE
METHYLPHENIDATE
IN THE
NETHERLANDS
|
|
|
Faber A1,
Van
Agthoven
M2,
Kalverdijk
L3,
Tobi H1,
De
Jong-van
den Berg
L1,
Annemans
L4,
Postma M1 |
|
|
1University
of
Groningen,
Groningen,
The
Netherlands,
2Janssen-Cilag
BV,
Tilburg,
The
Netherlands,
3University
Medical
Centre
Groningen,
Groningen,
The
Netherlands,
4Health
Economics
and
Outcomes
Research,
Brussels,
Belgium
|
|
PMH18
|
DIRECT
COST OF
DEPRESSION
–
ANALYSIS
OF A
GERMAN
CLAIMS
DATABASE
|
|
|
Gothe H1, Volmer T2, Höer A1, Mangiapane S1,
Runge C2,
Glaeske
G3,
Häussler
B1 |
|
|
1IGES
GmbH,
Berlin,
Germany,
2Wyeth
Pharma
GmbH,
Münster,
Germany,
3ZeS,
Centre
of
Social
Policy
Research,
Faculty
11:
Human
and
Health
Sciences,
University
of
Bremen,
Germany,
Bremen,
Germany
|
|
PMH19
|
IMPACT
OF
REMISSION
IN MAJOR
DEPRESSIVE
DISORDER
ON
ECONOMIC
BURDEN
OF
ILLNESS
IN
SWEDEN
|
|
|
Sobocki
P1, Ekman M1, Ågren H2, Runeson B2,
Jönsson
B3 |
|
|
1Stockholm
Health
Economics,
Stockholm,
Sweden,
2Karolinska
Institutet,
Stockholm,
Sweden,
3Stockholm
School
of
Economics,
Stockholm,
Sweden
|
|
PMH20
|
TREATMENT
PATHWAYS
AND COST
ASSESSMENT
OF
SCHIZOPHRENIA
IN
GREECE:
A
PRIMARY
ANALYSIS
|
|
|
Aggelopoulos
E1,
Geitona
M2,
Zaharakis
K3,
Kakavas
P4,
Karpouza
V5,
Kesidou
S6,
Kousoulakou
C7,
Bilanakis
N8,
Ollandezos
M9,
Papamichael
E10,
Papanicolaou
S11,
Chaidemenos
A12,
Chamogeorgakis
T13,
Kyriopoulos
J9 |
|
|
1Eginitio
Hospital,
University
of
Athens,
Athens,
Greece,
2University
of
Thessaly,
Volos,
Greece,
3Ygeia
Hospital,
Athens,
Greece,
4Sinouri
Hospital,
Athens,
Greece,
5Psychiatric
Hospital
of
Thessaloniki,
Thessaloniki,
Greece,
6Social
Insurance
Institute,
Athens,
Greece,
7Institute
foe
Economic
and
Industrial
Research,
Athens,
Greece,
8University
Hospital
of
Ioannina,
Ioannina,
Greece,
9National
School
of
Public
Health,
Athens,
Greece,
10General
Public
Hospital
Nikea,
Piraeus,
Greece,
11Janssen-Cilag
Pharmaceutical
SACI,
Athens,
Greece,
12Psychiatric
Hospital
of
Attica,
Athens,
Greece,
13Psychiatric
Hospital
of
Athens,
Dromokaitio,
Athens,
Greece
|
|
PMH21
|
COST-UTILITY
ANALYSIS
OF
ANTIDEPRESSANTS
FOR
SECOND-LINE
TREATMENT
OF MAJOR
DEPRESSIVE
DISORDER
|
|
|
Malone
DC |
|
|
University of Arizona, Tucson, AZ, USA |
|
PMH22
|
REHOSPITALIZATION
RATES IN
SCHIZOPHRENIA:
COMPREHENSIVE
LITERATURE
REVIEW
|
|
|
Rabinowitz
J1,
Ingham M2,
Caleo S3,
Levine
SZ1 |
|
|
1Bar
Ilan
University,
Ramat
Gan,
Israel,
2Johnson
&
Johnson,
Raritan,
NJ, USA,
3Janssen
Pharmaceutica
N.V,
Beerse,
Belgium
|
|
|
|
Health
Care Use
& Policy
Studies |
|
PMH23
|
PREDICTING
VIOLENT
OFFENDING
AMONG
MENTALLY
ILL IN A
MULTINATIONAL
SETTING
– NAIVE
BAYESIAN
FUSION
AND
MODEL
MERGING
WITH
P-COURSE
|
|
|
Soini EJ1, Rissanen T1, Tiihonen J2, Hodgins
S3,
Eronen M4,
Ryynänen
OP5 |
|
|
1University
of
Kuopio,
Canthia,
Kuopio,
Finland,
2University
of
Kuopio,
Niuvanniemi
Hospital,
Kuopio,
Finland,
3Institute
of
Psychiatry,
London,
UK,
4Vanha
Vaasa
Hospital,
Vaasa,
Finland,
5University
of
Kuopio,
Kuopio,
Finland
|
|
PMH24
|
ASSESSMENT
OF
RESOURCE
UTILISATION
IN
ADULTS
DIAGNOSED
WITH
DEPRESSION
IN THE
UK: A
GPRD-BASED
STUDY
|
|
|
Bineau S,
Saragoussi
D,
Despiegel
N, Toumi
M, Milea
D,
Verpillat
P |
|
|
H.
Lundbeck
A/S,
Paris,
France
|
|
PMH25
|
Withdrawn |
|
|
|
|
PMH26
|
RESOURCE
USE
AMONG
PATIENTS
WITH
SCHIZOPHRENIA
IN 5
EUROPEAN
COUNTRIES
|
|
|
Leeuwenkamp
O1,
Perry R2,
Morlock
R3,
Jones E2,
Taylor T4 |
|
|
1Organon
International,
Molenstraat,
Oss, The
Netherlands,
2Adelphi
Group
Products,
Bollington,
Cheshire,
UK,
3Pfizer
Inc, New
York,
NY, USA,
4Pfizer,
Ann
Arbor,
MI, USA
|
|
PMH27
|
COST-EFFECTIVENESS
OF
COGNITIVE-BEHAVIOURAL
THERAPY
(CBT)
FOR
MENTAL
ILLNESS:
AN
INTERNATIONAL
REVIEW
|
|
|
Payne K1, Myhr G2 |
|
|
1Caro
Research
Institute,
Montreal,
QC,
Canada,
2McGill
University,
Montreal,
QC,
Canada
|
|
PMH28
|
THE
MANAGEMENT
OF
SCHIZOPHRENIA
THROUGH
CLINICAL
PATHWAYS
|
|
|
Panella
M1, Demarchi ML2, Carnevale L2,
Castignoli
G2,
Valsesia
R2,
Vanetti
M2 |
|
|
1University
of
Eastern
Piedmont,
Novara,
Italy,
2Local
Health
Authority
13 of
Novara,
Novara,
Italy
|
|
PMH29
|
ACUTE
HOSPITALIZATION
IN THE
ELDERLY:RELATIONSHIP
WITH
PSYCHIATRIC
MORBIDITY
AND
SOCIAL
EQUITY
IN
HEALTH
CARE
ACESS IN
SINGAPORE
|
|
|
Ng TP1,
Feng L2,
Chiam PC3,
Kua EH1 |
|
|
1National
University
of
Singapore,
Singapore,
Singapore,
2National
Universtiy
of
Singapore,
Singapore,
Singapore,
3Institute
of
Mental
Health,
Singapore,
Singapore
|
|
PMH30
|
DIFFUSION
OF
NEWLY-APPROVED
GENERIC
DRUG
PRODUCT
USE
WITHIN A
STATE
EMPLOYEE
PRESCRIPTION
DRUG
PROGRAM:
A
COMPARISON
OF MAIL
ORDER
VERSUS
RETAIL
PHARMACY
CLAIMS
|
|
|
Johnsrud
M |
|
|
The
University
of Texas
at
Austin,
Austin,
TX, USA
|
|
PMH31
|
PREDICTORS
FOR
REHOSPITALIZATION
IN
PATIENTS
WITH
SCHIZOPHRENIA
|
|
|
Gothe H1, Höer A1, Seidlitz C1, Wittrup-Jensen
KU2,
Glaeske
G3 |
|
|
1IGES
GmbH;
pharmafacts
GmbH,
Berlin,
Germany,
2Janssen-Cilag
GmbH,
Neuss,
Germany,
3ZeS,
Centre
of
Social
Policy
Research,
Faculty
11:
Human
and
Health
Sciences,
University
of
Bremen,
Germany,
Bremen,
Germany
|
|
PMH32
|
ANALYSIS
OF A
MULTINATIONAL,
CROSS-SECTIONAL
SURVEY
OF
PHYSICIAN
DESCRIPTIONS
AND
PERCEPTIONS
OF
PATIENTS
WITH
NEGATIVE
SYMPTOMS
OF
SCHIZOPHRENIA
|
|
|
Leeuwenkamp
O1,
Perry R2,
Milligan
G2,
Morlock
R3,
Lecrubier
Y4 |
|
|
1Organon
International,
Molenstraat,
Oss, The
Netherlands,
2Adelphi
Group
Products,
Bollington,
Cheshire,
UK,
3Pfizer
Inc, New
York,
NY, USA,
4Hôpital
Pitié
Salpêtrière,
Paris,
France
|
|
|
|
Methods
&
Concepts |
|
PMH33
|
STRUCTURAL
EQUATION
MODELLING
OF
SCHIZOPHRENIA
EARLY
RETIREMENT
IN
GERMANY
|
|
|
Clouth J1, Eichmann F2, Davidov E3 |
|
|
1Lilly
Germany,
Bad
Homburg,
Germany,
2Kendle,
Munich,
Germany,
3Justus
Liebig
Universitaet
Giessen,
Giessen,
Germany
|
|
PMH34
|
IMPROVEMENTS
IN
ILLNESS
SEVERITY
AND
FUNCTIONING
IN
SCHIZOPHRENIC
PATIENTS
SWITCHED
TO
RISPERIDONE
LONG-ACTING
INJECTION
(RLAI):
|
|
|
Peuskens
J1,
Povey M2,
Diels J3,
Van der
Veken J4,
Jacobs A5 |
|
|
1Universitair
Psychiatrisch
Centrum,
KUL
Leuven,
Leuven,
Belgium,
2SGS
Biopharma,
Wavre,
Belgium,
3Janssen
Pharmaceutica,
beerse,
Belgium,
4Janssen
Cilag,
Berchem,
Belgium,
5Janssen
Pharmaceutica,
Beerse,
Belgium
|
|
PMH35
|
REDUCTION
IN
SUICIDAL
IDEATION
AND
VIOLENT
BEHAVIOUR
AFTER
SIX
MONTHS
OF
TREATMENT
WITH
LONG
ACTING
RISPERIDONE
IN
PATIENTS
ENROLLED
IN THE
ELECTRONIC
SCHIZOPHRENIA
ADHERENCE
TREATMENT
REGISTRY
(E-STAR)
|
|
|
Hustig H1, Peuskens J2, Olivares J3, Povey M4,
Jacobs A5 |
|
|
1Glenside
Hospital,
Fullarton,
South
Australia,
Australia,
2Universitair
Psychiatrisch
Centrum,
KUL
Leuven,
Leuven,
Belgium,
3Servicio
de
Psiquiatria
Hospital,
Vigo,
Spain,
4SGS
Biopharma,
Wavre,
Belgium,
5Janssen
Pharmaceutica,
Beerse,
Belgium
|
|
PMH36
|
6-MONTH
FOLLOW-UP
FROM THE
ELECTRONIC-
SCHIZOPHRENIA
ADHERENCE
TREATMENT
REGISTRY
(E-STAR)
OF
PATIENTS
IN SPAIN
WHO WERE
INITIATED
TO
RISPERIDONE
LONG-ACTING
INJECTION
(RLAI).
|
|
|
Olivares
J1,
Rodriguez
A2,
Povey M3,
Diels J4,
Jacobs A5 |
|
|
1Servicio
de
Psiquiatria
Hospital,
Vigo,
Spain,
2Janssen
cilag,
Madrid,
Spain,
3SGS
Biopharma,
Wavre,
Belgium,
4Janssen
Pharmaceutica
N.V,
Beerse,
Belgium,
5Janssen
Pharmaceutica,
Beerse,
Belgium
|
|
PMH37
|
BURDEN
OF
ILLNESS
OF
PATIENTS
WITH
ANXIETY
IN THE
UK
|
|
|
Makinson
G,
Koncz T,
Lister S |
|
|
Pfizer
Limited,
Tadworth,
Surrey,
UK
|
|
PMH38
|
A MODEL
TO
ASSESS
THE
COST-EFFECTIVENESS
OF NEW
TREATMENTS
FOR
DEPRESSION
|
|
|
Sobocki
P1, Ekman M1, Ågren H2, Jönsson B3 |
|
|
1Stockholm
Health
Economics,
Stockholm,
Stockholm,
Sweden,
2Karolinska
Institutet,
Stockholm,
Stockholm,
Sweden,
3Stockholm
School
of
Economics,
Stockholm,
Stockholm,
Sweden
|
|
PMH39
|
USE OF
VERBALLY
ADMINISTERED
AND
VERBALLY
ORIENTING
SCALES
TO
IMPROVE
DATA
COLLECTION.
|
|
|
Wood A1, Wenzel KW2 |
|
|
1ClinPhone,
Nottingham,
UK,
2ClinPhone,
Oregon,
WI, USA
|
|
PMH40
|
ASSESSING
SELECTION
BIAS ON
TREATMENT
EFFECTS
IN
OBSERVATIONAL
STUDIES
WITH
REPEATED
OUTCOME
MEASURES:
REGRESSION,
PROPENSITY
SCORING,
FIXED-EFFECTS
MODELS,
AND
BAYESIAN
ESTIMATION
METHODS
|
|
|
Ratcliffe
M |
|
|
Eli
Lilly
and
Company
Limited,
Windlesham,
Surrey,
UK
|
|
|
|
Patient
Reported
Outcomes |
|
PMH41
|
ANXIETY
DISORDERS:
THE
PATIENTS'
PERSPECTIVE
|
|
|
Wade AG1, Jorgensen TR2, Sapin C2, Le Lay A2,
François
C2 |
|
|
1CPS
Research,
Glasgow,
UK,
2Lundbeck
SAS,
Paris,
France
|
|
PMH42
|
QUALITY
OF LIFE
IN
PATIENTS
WITH
BIPOLAR
DISORDER
IN 5
EUROPEAN
COUNTRIES
|
|
|
Leeuwenkamp
O1,
Perry R2,
Morlock
R3,
Jones E2,
Taylor T4 |
|
|
1Organon
International
Inc,
Molenstraat,
Oss, The
Netherlands,
2Adelphi
Group
Products,
Bollington,
Cheshire,
UK,
3Pfizer
Inc, New
York,
NY, USA,
4Pfizer,
Ann
Arbor,
MI, USA
|
|
PMH43
|
IMPACT
OF
NEGATIVE
SYMPTOMS
ON
FUNCTIONING
OF
PATIENTS
WITH
SCHIZOPHRENIA
IN FIVE
EUROPEAN
COUNTRIES
|
|
|
Leeuwenkamp
O1,
Perry R2,
Morlock
R3,
Jones E2,
Taylor T4 |
|
|
1Organon
International,
Molenstraat,
Oss, The
Netherlands,
2Adelphi
Group
Products,
Bollington,
Cheshire,
UK,
3Pfizer
Inc, New
York,
NY, USA,
4Pfizer,
Ann
Arbor,
MI, USA
|
|
PMH44
|
TRAJECTORIES
OF
PATIENT
AND
CLINICIAN
REPORTED
ANTIPSYCHOTIC
COMPLIANCE
IN THE
SOHO
STUDY
AND
THEIR
CAUSES
AND
CONSEQUENCES
|
|
|
Croudace
TJ1,
Shi L2,
Novick D3,
Montgomery
W4,
Brown J3 |
|
|
1University
of
Cambridge,
Cambridge,
UK,
2Tulane
University,
New
Orleans,
LA, USA,
3Eli
Lilly
and
Company
Limited,
Windlesham,
Surrey,
UK,
4Eli
Lilly
and
Company,
Sydney,
NSW,
Australia
|
|
PMH45
|
CROSS-SECTIONAL
EVALUATION
OF
HEALTH
STATE
UTILITY
IN
SWEDISH
OUTPATIENTS
SUFFERING
FROM
MAJOR
DEPRESSIVE
DISORDER
|
|
|
Eriksson
T |
|
|
Department
of
Psychiatry,
Linköping,
Sweden
|
|
PMH46
|
ASSESSING
THE
CROSS-CULTURAL
COMPARABILITY
OF THE
CENTRE
FOR
EPIDEMIOLOGIC
STUDIES
DEPRESSION
SCALE
(CES-D)
|
|
|
Meads DM,
McKenna
SP,
Doward
LC |
|
|
Galen
Research,
Manchester,
UK
|
|
PMH47
|
MEASURING
RELAPSE
AFTER
ADOLESCENT
SUBSTANCE
ABUSE
TREATMENT:
A
PROPORTIONAL
HAZARD
APPROACH
|
|
|
Ciesla
JR,
Valle M,
Spear SF |
|
|
Northern
Illinois
University,
DeKalb,
IL, USA
|
|
|
|
OBESITY
|
|
Clinical
Outcomes
Studies |
|
POB1
|
ASSESSMENT
OF THE
CLINICAL
RISK
FACTORS
FOR
METABOLIC
SYNDROME
IN A
NATIONAL
PRIMARY
CARE
ELECTRONIC
HEALTH
RECORD
(EHR)
DATABASE
|
|
|
Brixner
D1, Said Q1, Oderda GM2 |
|
|
1The
University
of Utah
College
of
Pharmacy,
Salt
Lake
City,
UT, USA,
2University
of Utah,
Salt
Lake
City,
UT, USA
|
|
Cost
Studies |
|
POB2
|
COST-EFFECTIVENESS
OF
TREATING
CARDIOMETABOLIC
PATIENTS
WITH
RIMONABANT
(ACOMPLIA®)
IN A
DANISH
SETTING
|
|
|
Knudsen
MS1,
Poulsen
PB2,
Serup-Hansen
N3 |
|
|
1Muusmann
Research
&
Consulting
AS,
Copenhagen,
Denmark,
2Muusmann
Research
&
Consulting
AS,
Kolding,
Denmark,
3Sanofi-aventis,
Hoersholm,
Denmark
|
|
POB3
|
BURDEN
OF
ILLNESS
OF
ABDOMINAL
OBESITY:
A
RETROSPECTIVE
CHART
REVIEW
|
|
|
Strens D1, Lamotte M2, Fassotte C3, Annemans
L1 |
|
|
1IMS
Health,
Brussels,
Belgium,
2IMS
Health,
Brussel,
Brabant,
Belgium,
3sanofi-aventis,
Diegem,
Brabant,
Belgium
|
|
Methods
&
Concepts |
|
POB4
|
USING
CLAIMS
DATA TO
UNDERSTAND
THE
COSTS OF
DIFFERENT
HEALTH
STATES
FOR
PATIENTS
WITH
CARDIOMETABOLIC
RISK
|
|
|
Mangiapane
S1,
Gothe H1,
Schiffhorst
G1,
Aidelsburger
P2,
Fuchs SM2,
Wasem J3,
Glaeske
G4,
Häussler
B1 |
|
|
1IGES
GmbH,
Berlin,
Germany,
2Carem
GmbH,
Sauerlach,
Germany,
3University
of
Duisburg-Essen,
Essen,
Germany,
4ZeS,
Centre
of
Social
Policy
Research,
Faculty
11:
Human
and
Health
Sciences,
University
of
Bremen,
Germany,
Bremen,
Germany
|
|
POB5
|
A
MODELLED
COST-EFFECTIVENESS
EVALUATION
OF
SIBUTRAMINE
THERAPY
IN A
HIGH
RISK
OBESE
POPULATION
|
|
|
Walters
N1, Makino K1, Hutchinson J1, Shorter
N2,
Swanson
M2,
Schulz M2 |
|
|
1M-TAG,
a unit
of IMS,
Chatswood,
NSW,
Australia,
2Abbott
Australasia,
Botany,
NSW,
Australia
|
|
POB6
|
IN
EUROPE,
HOW
REPRESENTATIVE
ARE
OVERWEIGHT/OBESE
SUBJECTS
RECRUITED
VIA THE
INTERNET?
|
|
|
Zhou X1,
Radigue
C2,
Allshouse
AA3,
Gilsenan
A1 |
|
|
1RTI
Health
Solutions,
Raleigh,
NC, USA,
2Sanofi
Synthelabo
Recherche,
Paris,
France,
3RTI
Health
Solutions,
North
Carolina,
NC, USA
|
|
|
|
Patient
Reported
Outcomes |
|
POB7
|
THE
RELATIONSHIP
BETWEEN
WEIGHT
CHANGES
AND
RELATED
CHANGES
IN
HEALTH-RELATED
UTILITY:
EVIDENCE
OF CAUSE
AND
AFFECT
|
|
|
Woehl A,
Currie
CJ |
|
|
Cardiff University, Cardiff, UK |
|
POB8
|
THE
IMPACT
OF BODY
WEIGHT
ON
UTILITY
SCORES
IN
PATIENTS
WITH
TYPE 2
DIABETES
|
|
|
Dennett
SL1,
Secnik K2,
Yurgin
NR2,
McDonald-Everett
CM2 |
|
|
1Strategic
Health
Outcomes,
Carmel,
IN, USA,
2Eli
Lilly
and
Company,
Indianapolis,
IN, USA
|
|
POB9
|
DEVELOPMENT
OF A NEW
QUESTIONNAIRE
FOR
IDENTIFING
PREDICTIVE
FACTORS
INFLUENCING
WEIGHT
LOSS
THERAPIES
|
|
|
Ruíz MA1, Costa M1, Rubio MA2, Iruarrizaga I3,
Almendro
C4,
Moreno B5,
Salvador
J6,
Antón J7,
Bande C8,
García
Pulgar
MS9 |
|
|
1Universidad
Autónoma
de
Madrid,
Madrid,
Spain,
2Hospital
Clínico
Universitario
San
Carlos,
Madrid,
Spain,
3Universidad
Complutense
de
Madrid,
Madrid,
Spain,
4Centro
de Salud
Torrent,
Valencia,
Spain,
5Hospital
General
Universitario
Gregorio
Marañón,
Madrid,
Spain,
6Clínica
Universitaria
de
Navarra,
Pamplona/Iruña,
Spain,
7CAP
Manso,
Barcelona,
Spain,
8Complejo
Hospitalario
Cristal-Piñor,
Orense,
Spain,
9Roche
Farma
S.A,
Madrid,
Spain
|
|
POB10
|
RIMONABANT
IMPROVES
HEALTH-RELATED
QUALITY
OF LIFE
IN
OVERWEIGHT/OBESE
PATIENTS
WITH
TYPE 2
DIABETES:
RIO-DIABETES
STUDY
|
|
|
Kolotkin
RL1,
Crosby
RD2,
Scheen A3 |
|
|
1Duke
University
Medical
Center,
Durham,
NC, USA,
2Neuropsychiatric
Research
Institute,
Fargo,
ND, USA,
3University
of
Liège,
Liège,
Belgium
|
|
|
|
PAIN
|
|
Clinical
Outcomes
Studies |
|
PPN1
|
INTRAVENOUS
PARACETAMOL
IN
POSTOPERATIVE
PAIN
MANAGEMENT
–
SYSTEMATIC
REVIEW
AND META
ANALYSIS
OF
RANDOMIZED
CONTROLLED
TRIALS
|
|
|
Golicki
D,
Niewada
M |
|
|
Medical
University
of
Warsaw,
Warsaw,
Poland
|
|
PPN2
|
META-ANALYSIS
OF
DULOXETINE
VS.
PREGABALIN
AND
GABAPENTIN
IN THE
TREATMENT
OF
PERIPHERAL
DIABETIC
NEUROPATHIC
PAIN
|
|
|
Quilici
S1, Chancellor J1, Lothgren M2, Simon
D3,
Said G4,
Le TK5,
Garcia-Cebrian
A6,
Monz B7,
Kajdasz
D5 |
|
|
1i3
Innovus,
Uxbridge,
Middlesex,
UK,
2i3
Innovus
(Employed
by
Innovus
at the
time the
research
was
performed),
Uxbridge,
Middlesex,
UK,
3La
Pitié-Salpêtrière
Hospital,
Paris,
France,
4Hôpital
de
Bicêtre,
Le
Kremlin-Bicêtre,
France,
5Eli
Lilly,
Indianapolis,
IN, USA,
6Eli
Lilly
and
Company
Limited,
Basingstoke,
UK,
7Boehringer
Ingelheim
GmbH,
Ingelheim,
Germany
|
|
PPN3
|
SAFETY
OF
METAMIZOLE,
KETOPROFEN
AND
PARACETAMOL
–
ANALYSIS
OF DATA
FROM WHO
PROGRAMME
FOR
INTERNATIONAL
DRUG
MONITORING
|
|
|
Golicki
D1, Niewada M1, Grygier K2, Scibiorski
C2 |
|
|
1Medical
University
of
Warsaw,
Warsaw,
Poland,
2Bristol-Myers
Squibb,
Warsaw,
Poland
|
|
Cost
Studies |
|
PPN4
|
ECONOMIC
EVALUATION
COMPARING
BMP-2
(INDUCTOSTM)
VERSUS
CURRENT
TREATMENT
IN
CHRONIC
LOWER
BACK
PAIN IN
THE
SPANISH
SETTING
|
|
|
Serrano
D1, Rodríguez J2, Lizan L3, Poyatos J4,
Chhabra
A5 |
|
|
1Medtronic
Iberica
S.A,
Madrid,
Spain,
2Medtronic
Iberia,
Madrid,
Madrid,
Spain,
3Universidad
Jaume I,
Castelló
de la
Plana,
Spain,
4Hospital
General
de
Castellón,
Castellón
de la
Plana,
Spain,
5Medtronic
Europe
SA,
Tolochenaz,
Switzerland
|
|
|
|
STROKE
|
|
Cost
Studies |
|
PST1
|
BUDGETARY
IMPACT
ANALYSIS
OF
RECOMBINANT
ACTIVATED
FACTOR
VII IN
THE
TREATMENT
OF
INTRACEREBRAL
HEMORRHAGE:
A US
HEALTH
PLAN
PERSPECTIVE
|
|
|
Earnshaw
SR1,
Wilson
MR1,
Joshi AV2 |
|
|
1RTI
Health
Solutions,
Research
Triangle
Park,
NC, USA,
2Novo
Nordisk,
Inc,
Princeton,
NJ, USA
|
|
PST2
|
STROKE
PATIENT
RESOURCE
USE AND
CAREGIVER
BURDEN
OUTCOMES
BY SEVERITY
(RECOVERY)
STUDY:
METHODS
AND
PRELIMINARY
GERMAN
RESULTS
|
|
|
Payne K1, Caro JJ2, Proskorovsky I1, Lordan
N2,
Huybrechts
KF2,
Ishak KJ1,
Rylander
A3,
Kolominsky-Rabas
P4 |
|
|
1Caro
Research
Institute,
Montreal,
QC,
Canada,
2Caro
Research
Institute,
Concord,
MA, USA,
3AstraZeneca
R&D
Sodertalje,
Sodertalje,
Sweden,
4Interdisciplinary
Center
for
Public
Health
Studies.
University
of
Erlangen-Nuremberg,
Erlangen,
Germany
|
|
PST3
|
RESOURCE
UTILIZATION
AND
COSTS OF
STROKES
IN A
THIRD
LEVEL
HOSPITAL
IN
MéXICO
|
|
|
Carbajal
A1,
Soto H2,
Salazar
J3,
Zanela O4,
Talavera
J5 |
|
|
1Hospital
de
Especialidades,
IMSS,
Delegacion
Cuauhtemoc,
Mexico
D.F,
Mexico,
2Universidad
del
Estado
de
Mexico,
Toluca,
Edo de
Mexico,
Mexico,
3Hospital
de
Especialidades,
IMSS,
Delegación
Cuauhtemoc,
Mexico
D.F,
Mexico,
4Universidad
del
Estado
De
México,
Toluca,
Estado
de
Mexico,
Mexico,
5Hospital
de
especialidades,
IMSS,
Delegacion
Cuauhtemoc,
México
D.F,
Mexico
|
|
PST4
|
DIFFERENCES
IN
DISCHARGE
LOCATION
FOR
PATIENTS
WITH
MULTIPLE
ISCHEMIC
STROKE
ADMISSIONS:
IMPLICATIONS
FOR
POST-ACUTE
CARE
COSTS
|
|
|
O'Brien
JA,
Duran
PA, Caro
JJ |
|
|
Caro
Research
Institute,
Concord,
MA, USA
|
|
Health
Care Use
& Policy
Studies |
|
PST5
|
THE
WEAKNESS
OF
TEAMWORK
BETWEEN
NURSES
AND
PHYSIOTHERAPISTS
IN
CARING
FOR
STROKE
PATIENTS
IN
HUNGARY
|
|
|
Betlehem
J1,
Horváth
M1,
Boncz I2,
Sebestyén
A2 |
|
|
1University
of Pécs,
Pécs,
Hungary,
2National
Health
Insurance
Fund
Administration
(OEP),
Budapest,
Hungary
|
|
Patient
Reported
Outcomes |
|
PST6
|
UTILITY
LOSS AND
INDIRECT
COSTS
AFTER
STROKE
IN
SWEDEN
|
|
|
Lindgren
P1,
Glader
EL2,
Jönsson
B3 |
|
|
1Stockholm
Health
Economics,
Stockholm,
Sweden,
2Umeå
Universitet,
Umeå,
Sweden,
3Stockholm
School
of
Economics,
Stockholm,
Sweden
|
|
|
|
SURGERY
|
|
Cost
Studies |
|
PSU1
|
A COST-EFFECTIVENESS EVALUATION OF VACUUM ASSISTED CLOSURE (V.A.C. THERAPY) TREATMENT FOR DEHISCED CHEST WOUND PATIENTS
|
|
|
Song D1, Miller E2, Keith MS3 |
|
|
1University
of
Chicago,
Chicago,
IL, USA,
2KCI,
San
Antonio,
TX, USA,
3KCI
USA,
Inc, San
Antonio,
TX, USA
|
|
PSU2
|
ECONOMIC
EVALUATION
COMPARING
FROM
HOME TO
OPERATION
AND
CONVENTIONAL
PROCESS
OF
LAPAROSCOPIC
CHOLECYSTECTOMY:
PROSPECTIVE
RANDOMIZED
CONTROLLED
TRIAL
|
|
|
Soini EJ1, Keränen J2, Ryynänen OP3, Keränen
U4 |
|
|
1Department
of
Social
Pharmacy,
Department
of
Health
Policy
and
Management,
University
of
Kuopio,
Kuopio,
Finland,
2Faculty
of
Medicine,
University
of
Kuopio,
Kuopio,
Finland,
3Department
of
Public
Health
and
General
Practice,
University
of
Kuopio,
Kuopio,
Finland,
4Hospital
District
of
Helsinki
and
Uusimaa,
Department
of
Operative
Specialties,
Hyvinkää
Hospital
Region,
Hyvinkää,
Finland
|
|
PSU3
|
DEMOGRAPHIC
PREDICTORS
OF
RESOURCE
UTILIZATION
AND
COSTS OF
SOLID
ORGAN
TRANSPLANTATION
IN
BRITISH
COLUMBIA,
CANADA.
|
|
|
Levy AR, Sobolev B2, James D3, Sullivan SD4,
Partovi
N5,
Barrable
W55,
Levy R5 |
|
|
1Oxford
Outcomes
Ltd,
Vancouver,
BC,
Canada,
2University
of
British
Columbia,
Vancouver,
BC,
Canada,
3St
Paul's
Hospital,
Vancouver,
BC,
Canada,
4University
of
Washington,
Seattle,
WA, USA,
5BC
Transplant
Society,
Vancouver,
BC,
Canada
|
|
Cost
Studies |
|
PSU4
|
VENTRAL,
UMBILICAL,
AND
INGUINAL
HERNIA:
REVIEW
OF THE
CURRENT
LITERATURE
|
|
|
De Jonge
P1,
Llyod A1,
Tan R2,
Narewska
J1,
Doyle S3,
Nafees B1 |
|
|
1UBC,
London,
UK,
2Ethicon,
Livingston,
UK,
3United
BioSource
Corporation,
London,
London,
UK
|
|
|
|
|
|
9th Annual European Congress Main Pagee
|
|
